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Firms have increasingly offshored manufacturing to foreign countries in the 
past decades due to the expected benefits driven by low manufacturing costs in 
developing economies. With changes in competition and government pressure for 
domestic production, however, manufacturing firms have reevaluated these decisions 
leading some to reshore manufacturing activities. Recent studies have investigated 
various reshoring motivations and developed conceptual frameworks that can be used 
as tools in reshoring decisions. However, the complexity in decision making remains 
high due to product and industry specific traits impacting the manufacturing process. 
Examples include the increasing concern over product quality and changing 
regulations. Two industries that are heavily impacted by reshoring decisions are 
medical device and pharmaceutical companies. Theoretical support for these decisions 
have been limited with most studies relying on Transaction Cost Economics (TCE) 
and Resource Based Review (RBV). While valuable, these theories are insufficient to 
explain the growing number of decision variables involved in reshoring. This study 
proposes that Dunning’s ownership, location, and internalization (OLI) framework 
explains more of the recent decision variables related to reshoring. Based on four sub-
paradigms of the OLI framework, this study develops a reshoring decision model 
using a systematic literature review (SLR) and semi-structured interviews. Then, the 
study tests the model using a large-scale survey. Results show that reshoring decisions 
in the medical device and pharmaceutical industries are dominated by quality and 
regulatory requirements that involve long and complex validation processes, among 
others. Lastly, using authentic industry parameters in an analytical model, this study 
demonstrates the impact of reshoring and offshoring cost factors on reshoring 
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Defined as “moving manufacturing back to the country of its parent company” 
(Ellram, 2013, p.3), reshoring decisions are gaining interest in recent years as a 
strategic economic activity for businesses with corresponding societal benefits. In that 
sense, reshoring can be viewed as an activity that supports organizational 
sustainability according to the triple bottom line (TBL) framework by Elkington 
(1994), which includes economic, social, and environmental sustainability. Yun et al. 
(2019) find that current studies on the interaction between economic and social 
performance have a narrow focus on charitable corporate social responsibility (CSR) 
activities because of the difficulty in developing measures for social performance. The 
limited scope of social performance relies on the benevolence of corporations, for 
example, ranging from cash donations to assignments of company resources to 
charities. It often does not associate CSR with an outlay of resources contributing to 
economic performance at the firm level. However, corporate consideration of 
reshoring can be understood as an important strategic decision that improves an 
organization’s economic sustainability that leads to business continuity as well as 
social sustainability. Thus, a company’s reshoring decision to increase profitability 
can also improve social performance by supporting local suppliers, for example, 
(Ashby, 2016) and thus by creating employment opportunities in society.  
Job creation and tax benefits are considered positive impacts of reshoring by 
improving the lives of stakeholders in home countries that support domestic 
production. This may be particularly true for manufacturing companies in the 
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healthcare industry which provide products that have a critical impact on human well-
being and revenue generation. These firms have increasingly outsourced 
manufacturing to foreign countries due to the expected benefits driven by low costs in 
developing economies. However, with changes in the internal and external 
environment and government pressure for domestic production, some manufacturing 
firms have reevaluated their offshoring decisions and reshored manufacturing. Recent 
studies have investigated various reshoring motivations and have developed 
conceptual frameworks that can be used as tools in reshoring decisions. However, 
these tools are limited due to the increasing complexity in decision making driven by 
product and industry specific traits. In healthcare, pharmaceutical and medical device 
companies are hugely impacted, especially around product quality and changing 
regulations.  
When a firm considers reshoring, there are three possible outcomes: 
1) Full reshoring: where a firm moves all production back to a home country; 
2) Partial reshoring: where a firm moves only partial production back to a home 
country while keeping the remainder in the foreign location(s); and 
3) No Reshoring: where a firm keeps all production in a foreign location(s). 
Given rational economic models, a firm will select the option that provides the 
greatest benefit. The outcome that achieves the best performance is referred to as 
“right-shoring” (Tate and Bals, 2017; Joubioux and Vanpoucke, 2016). Right-shoring 
involves a review of a company’s “shoring” options for repositioning manufacturing 
to meet firm objectives (Tate and Bals, 2017). This process involves a consideration of 
the original offshoring motivation as well as reshoring drivers that may differ from the 
3 
 
original offshoring decision. This decision requires a deeper understanding of both 
qualitative and quantitative variables in the decision process. Thus, this study attempts 
to investigate the factors that are considered in reshoring decisions and how these 
factors can lead to right-shoring. A better understanding of these decision making 
factors will improve organizational sustainability based on the social and economic 
contribution of companies. 
 
Research questions 
The purpose of the study is to examine factors that impact manufacturing 
reshoring decisions in the context of the healthcare industry and investigate how 
reshoring can contribute to a right-shoring decision. This study achieves this goal by 
answering the following research questions: 
• What factors impact manufacturing reshoring decisions in the healthcare 
industry? 
• How do these factors impact reshoring decisions of medical device and 
pharmaceutical companies? 
• What is an optimal right-shoring solution? 
By answering these questions, this study makes contributions to the literature in 
four areas. First, it is the first study to develop and empirically test a decision model 
for reshoring in the context of medical devices and pharmaceuticals. The extant 
literature suggests that variables impacting reshoring decisions vary from firm to firm, 
product to product, and thus firm and product specific approaches are needed to 
understand reshoring factors. Second, this study treats reshoring as an investment 
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decision based on Dunning’s ownership, location, and internalization (OLI) 
investment framework (Dunning, 1980). The study empirically examines why 
companies consider reshoring decisions that can differ from their original offshoring 
decisions. This provides a theoretical lens to see reshoring as a strategic location and 
sourcing decision without treating reshoring simply as a temporary condition driven 
by short-term cost benefits or immediate political and economic stability. Third, this 
study also suggests that reshoring results in a positive interaction between economic 
and social variables that improve sustainability without reliance on CSR or charitable 
activities. Fourth, based on the results of the interviews and survey, a rudimentary 
analytical model demonstrates how right-shoring can lead to optimal solutions for 
reshoring manufacturing in healthcare. This model is a practical tool that uses 
transportation cost as a differentiator that impacts reshoring decisions by examining 
the balance between offshoring and reshoring. It shows that an optimal balance may 
exist to inform right-shoring decisions. 
 
Multi-method approach 
To answer the research questions, this study uses multiple methods including:  
1) Systematic literature review (SLR)  
2) Semi-structured interviews 
3) Large-scale survey 
4) Rudimentary analytical model  
An overview of how these methods are used is described sequentially in Figure 1 
followed by a detailed explanation of the procedure.  
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First, a systematic literature review (SLR) is conducted to identify current 
research gaps and the existing variables that are used in reshoring decisions. The 
identified variables are categorized based on a theoretical framework and developed 
into a conceptual model. Since the topic of reshoring is still exploratory, a series of 
semi-structured interviews is conducted with practitioners in the medical device and 
pharmaceutical industry to identify new variables relevant to this research. The 
interviews are continued until theoretical saturation is reached (Robinson, 2014). 
Theoretical saturation is the point where no new information is being discovered 
through data collection, in this case interviews (Suddaby, 2006). The topic is 
theoretically saturated with knowledge. It is “theoretical” because it is practically 
impossible to demonstrate that all knowledge is captured through any methodology.  
The variables found in the interview process are incorporated into the conceptual 
model and some parameters are eventually used in an analytical model. 
To empirically test the conceptual model of reshoring factors, a large-scale 
survey is employed using Dillman’s (2009) approach. This procedure contains four 
steps: Step 1 (S1) - survey development, Step 2 (S2) - pre-test, Step 3 (S3) - pilot-test, 
and Step 4 (S4) - administration (see Figure 1). A questionnaire is developed based on 
the literature and the conceptual model. The initial questionnaire includes questions on 
demographic information and 65 items from the conceptual model. Four questions on 
product complexity, product standardization, technology intensity, and labor intensity 
are added to measure product characteristics.  
Then, the survey is pre-tested for readability, face validity, and content validity 
on a group of academics and MBA students (Pre-test 1).  
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Figure 1. Description of methodological procedure 
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Many revisions are recommended to an extent where a second pre-test is warranted 
(Pre-test 2). After the revisions are made, the second pre-test is conducted on a group 
of 14 mid-level managers and scientists in the medical device and pharmaceutical 
industries. As recommended by Dillman (2009; 2014), the second pre-test is 
conducted in the presence of the researcher so that body language can be observed and 
the respondents can ask questions and provide oral feedback. To facilitate this, Pre-test 
2 includes a group debriefing assessment which identifies major issues demanding a 
reevaluation of the measurement items and topic clarification (Ruel et al., 2016). The 
participants reported that, 
1) while the variables and factors reflect their experience, some of the 
conceptual associations between the variables and factors are incorrect;  
2) the survey is too long at 65 questions, driven by too many redundant items 
measuring variables that can be measured by single items; and  
3) the questions are too wordy and description of variables can be simplified 
because the instrument will be delivered to professionals in the field.  
To correct associations between the variables and factors, a multi-round Q-sort 
is conducted with the Pre-test 2 group using a Delphi approach (McKnight, 2008; 
Brady, 2015), which is recommended as a method to assess reliability and construct 
validity at the pre-testing stage (Nahm et al., 2002). A Delphi systematically allows 
participants to see and hear the responses of others when classifying variables and 
their relationships. As a result, the group reclassified the 65 indicators into 15 different 
categories, and items with unnecessary redundancy were reevaluated and excluded, 
resulting in a reduction of the instrument to 54 indicators (items); 15 categories were 
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the higher order grouping variables while the 54 were individual reshoring drivers. 
This reclassification allowed for refutability of the variables that do not conceptually 
associate with the theoretical framework. A second round of Delphi sought consensus 
on classification. The 19 indicators that did not achieve over 75% of agreement 
(McKnight, 2008) in the process were dropped. After another round of revisions based 
on the dropped items, a new survey instrument containing 35 items was tested again 
on the same Pre-test 2 group. No further revisions were recommended.  
To minimize potential sampling bias due to the convenience sample for Pre-
test 2, a pilot-test is then performed on the new 35-item instrument with a new group 
of 16 respondents from the medical device industry and 14 respondents from the 
pharmaceutical industry. Unlike the Pre-test 2 group who work for a company that 
manufactures both pharmaceutical and medical devices that used complimentary 
technologies, the pilot-test group work for companies that only manufacture one or the 
other. The results of the pilot-test lead to a minor revision to the introductory 
statements and no changes to the 35 items. Due to only minor revisions to the 
instrument, a second pilot-test is deemed unnecessary.  
The final survey is administered online to mid-to-upper level managers and 
technical personnel in medical device and pharmaceutical manufacturing firms in the 
U.S. Since there are no substantial revisions to the instrument resulting from the pilot-
test group, the pilot-test responses are retained as part of the full sample. The first 30 
responses from the final survey sample are compared with the pilot-test responses. A 
simple correlation was used to compare the two samples. The correlation between the 
two groups is significant at r = .60, suggesting that methods bias is not affecting the 
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responses. It is important to note that approximately 50% of usable responses are 
collected directly by the researcher while 50% of usable responses are collected 
through a research firm that charge a fee for their services.  
Lastly, a rudimentary analytical model is developed based on real-world 
parameters collected during the interviews. The model demonstrates how to 
quantitatively optimize a right-shoring decision when faced with both domestic and 
foreign production options. The model uses parameters from a real medical device 
company based on assumptions that are context specific. 
The rest of this study is organized as follows. Section 2 presents the 
methodology and the result of the systematic literature review, which is followed by 
semi-structured interviews in Section 3. The measurement model is tested using a 
survey and the results are discussed in Section 4. In Section 5, an analytical model for 
right-shoring is proposed. Conclusion, limitations, and future direction of this 
dissertation are discussed in Sections 6 and 7. As a result, this study suggests how 













Studies (Hilletofth et al., 2019; Tate and Bals, 2017; Joubioux and Vanpoucke, 
2016) use the term “right-shoring” in relation to recently increasing reshoring 
activities used in strategic location decisions that originated from offshoring. Likewise, 
the term “right-shoring” in this research refers to location decisions based on 
estimating the balance of domestic versus foreign (offshored) production to achieve 
corporate objectives. While the first part of the study focuses on reshoring as the 
reverse strategic decision to offshoring, the later part of the study demonstrates, based 
on this understanding, how reshoring can be considered a right-shoring decision using 
an analytical model. 
 
Theoretical background 
As a theory in international business, the ownership, location, and internalization 
(OLI) framework, also known as the eclectic paradigm, was initially developed by 
Dunning (1973) to explain foreign direct investment (FDI) and foreign activities of 
multinational enterprises (MNEs). Dunning (1973) developed the theory to explain 
why firms invest overseas and what determines the amount and composition of 
international production. The OLI framework explains that three determinants are 
considered in internationalization impacting propensity to engage in foreign 
production: ownership advantages, location advantages, and internalization advantages. 
Ownership advantage is the possession of a certain valuable, rare, hard-to-imitate, and 
an organizationally embedded resource that allows a company to have a competitive 
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advantage. Location advantage is the advantage associated with particular locations 
that are separate from ownership advantages which may or may not be transferable 
from the locations or can be combined with products in a home country. 
Internalization advantage is an advantage gained through direct ownership of 
production in another country rather than producing through a partnership 
arrangement in the foreign country, such as licensing, contract manufacturing, or a 
joint venture. In the presence of all three of these advantages, firms are likely to invest 
in foreign production options such as offshoring.  
Extending the theory to include observable factors, Dunning (1998; 2000) 
developed four sub-paradigms of these advantages. They are: 
1) Resource seeking (RS): to gain access to natural resources, such as agricultural 
products, unskilled or skilled labor, unique technology; supply oriented;  
2) Market seeking (MS): to satisfy growing or existing demand in a particular 
foreign market(s); 
3) Efficiency seeking (ES): to promote a more efficient division of labor or 
specialization of an existing portfolio of foreign and domestic assets; related to 
RS and MS; and 
4) Strategic asset seeking (SAS): to protect or augment the existing ownership 
specific advantages of the investing firms or to reduce those of the competitors. 
Studies by Ellram et al. (2013) and Ancarani et al. (2015) use these sub-paradigms 
of the OLI framework to conceptually categorize reshoring drivers discovered to that 
point. These studies explain that reshoring occurs as a consequence of the changes in 
the advantages in the OLI framework (Ellram, 2013; Johansson and Olhager, 2018) 
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since reshoring requires consideration of internationalization factors (Presley et al., 
2016). Thus, firms decide to withdraw due to the relative decrease in ownership, 
location, and internalization advantages and the four sub-paradigms that explain 
specific motivations. Ancarani et al. (2015) find an association between the duration 
of offshored firms and reshoring motivations, such as technology, customization, 
decrease in cost differentials, physical distance, organization archetypes, firm size, and 
“made-in” effect. In the same vein, looking at reshoring as a fundamentally strategic 
location decision, this study uses the four sub-paradigms of location advantage as the 
theoretical framework to conceptualize and empirically test a reshoring model. 
 
Systematic literature review (SLR) 
A systematic literature review (SLR) (Tranfield et al., 2003; Durach et al., 
2017) is used as a structured approach to identify a gap in the reshoring literature and 
identify reshoring drivers in the extant literature. The review process follows three 
major stages promoted by Tranfield et al. (2003), and six detailed steps suggested by 
Durach et al. (2017). The three stages include Stage I planning the review, Stage II 
conducting the review, and Stage III reporting and dissemination of the results. 
 
Stage I – Review protocol 
In Stage I, a review protocol is developed based on the research questions to guide 
how the review should be conducted in Stage II. Due to the exploratory nature of the 
topic, the reshoring concept is also characterized by other terms, such as back-shoring, 
back-reshoring, and on-shoring. Thus, search keywords such as “reshoring”, “back-
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shoring”, “on-shoring”, and “manufacturing relocation” were used for an initial search 
of the articles using ABI/INFORM and Google Scholar as the primary and secondary 
database. While ABI/INFORM identifies articles focusing on business, Google 
Scholar provides a wider range of scholarly resources that may be missing in the ABI 
search (Howland et al., 2009). Because of the small number of studies on reshoring, 
the initial search included all of the relevant sources, such as white papers, conference 
proceedings, dissertations/theses, books, and journal articles published between 2009 
and 2018. Reviewing references of these sources allowed for a thorough search 
process. After a review, only scholarly journal articles were included in the data 
synthesis and analysis to improve the rigor of the study (Gunasekaran and Ngai, 2005). 
The review excluded articles that are merely anecdotal opinions without scientific 
evidence. Scholarly articles were chosen based on two major inclusion criteria: 
• Articles that have a primary focus on reshoring drivers and/or motivations, or 
that discuss at least one reshoring motivation; and 
• Articles that are published in scholarly journals. 
The reviewed articles are not limited to a certain list of selected journals. They include 
journals in operations, supply chain management, and technology with various 
methodological emphases and topics. 
As systematic coding and analysis are important in SLR, this study uses a 
canonical coding approach promoted by Carnevalli and Miguel (2008). Detailed 
coding schemes in Appendix A represent a quality evaluation of the articles based on 
research objectives, which includes: 
1) publication year, 
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2) name of journal, 
3) methodology, 
4) research type, 
5) definition of reshoring, 
6) research context – country and industry, 
7) how reshoring is initiated: reverse of a previous offshoring failure, strategic 
choice, or reaction to changes in business environment, 
8) research theme, 
9) unit of analysis, 
10) documentation type, and 
11) motivations of reshoring. 
 
Stage II – Review 
As a result of the initial search and article selection process, 52 scholarly 
articles in 28 different journal outlets are identified. These articles are coded based on 
the name of the journal in Appendix B. Data is extracted with a primary focus on 
reshoring drivers that are formed into a conceptual model. Evaluation of data quality is 
conducted based on the review protocol in Stage I. The results are further explained in 




Stage III – Report and dissemination 
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Fifty-two studies published from 2009 to 2018 are identified for data analysis. 
Most of the articles use conceptual and empirical methods, such as literature reviews, 
surveys, and case studies that discuss at least one reshoring motivation. 
Existing studies empirically examine the motivations for reshoring decisions 
mainly in Europe (i.e. Germany, Finland, Sweden, and Denmark) and the U.S. Studies 
suggest that reshoring decisions can differ by context due to various characteristics, 
such as firm size, industry, product customization, and ownership mode (Benstead et 
al., 2017; Ancarani et al., 2015). Industry can be a particularly important factor in 
relocation decisions (Pennings and Sleuwaegan, 2000; Kinkel, 2012; Fratocchi et al., 
2014) because of the relation to the initial motivation of offshored manufacturing 
activities.  
As the extant literature suggests, initial offshoring activities are primarily 
driven by low cost advantage. Both labor-intensive and technology-intensive 
manufacturing are initially offshored based on resource and market seeking 
motivations. However, labor-intensive manufacturing is focused on low labor costs 
while technology-intensive manufacturing seeks to locate overseas to acquire unique 
technology or knowledge. In the same vein, industry is prone to specific reshoring 
motivations having a significant impact on “reshoring propensity” as suggested by 
Canham and Hamilton (2013). The product type as well as industry are important in 
that production requiring high levels of direct labor is likely to migrate to low cost 
regions, not the final market which the products serve (MacCormack et al., 1994). 
Furthermore, products with higher levels of customization have higher manufacturing 
complexity due to limited ability to control outsourced manufacturers (Hartman et al., 
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2017). Offshoring strategy is still common for these products such as electronics and 
automotive (Ciravegna et al., 2013; Mudambi and Venzin, 2010). Offshoring these 
products often results in longer lead times since they require close coordination and 
interaction among suppliers, especially those with a high degree of customization 
(Ancarani et al., 2015). 
Canham and Hamilton (2013) find that context has a significant impact on 
reshoring decisions. The context derived from current research is limited because it 
focuses on a certain labor-intensive industry or a “one-size-fits-all” approach versus a 
high-tech, high-skilled, or highly-regulated industry. The existing reshoring 
frameworks are developed to be used industry-wide. A few studies (Canham and 
Hamilton, 2013; Johansson and Olhager, 2018) examine how firm-level characteristics 
such as manufacturing process, export intensity, research and development (R&D) 
intensity, production complexity, product specialization, production volume, and labor 
intensity affect offshoring decisions. However, there has been no study which 
evaluates reshoring decision factors at the industry level, which has been shown to be 
important in offshoring. More specifically, this study finds no research on reshoring 
conducted in the context of the healthcare-related manufacturing industry that 
differentiates it from reshoring decisions in other industries.  
Among 52 studies on reshoring published from 2009 to 2018, nine studies 
(Kinkel and Maloca, 2009; Kinkel, 2012; Tate et al., 2014; Fratocchi et al., 2016; Zhai 
et al., 2016; Delis et al., 2017; Kim et al., 2017; Heikkila et al., 2018; Johansson et al., 
2018) investigate motivations for reshoring including cases in the medical, 
pharmaceutical, biotech, or biomedical industry sectors. None of these studies 
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examine how their reshoring motivations may differ from other industry sectors. 
Studies that examine reshoring in a standalone industry focus on metal and electrical 
(Kinkel, 2014; Brennan et al., 2015), shoes and apparel (Mezzadri, 2014; Martinez-
Mora and Merino, 2014; Baraldi et al., 2018), and electronics and automotive 
(Ancarani et al., 2015). Detailed classification of the articles in the literature review is 
presented in Appendix B. Appendix C describes the industry sectors that are addressed 
in the reviewed articles based on the International Standard Industrial Classification of 
All Economic Activities (ISIC) code. 
Appendix D summarizes the reshoring drivers identified in the literature 
review. In total, 122 concepts and topics are found to impact reshoring decisions based 
on the search criteria. Column three in Appendix D provides the references. The result 
show that factors in reshoring manufacturing tend to be dominated by variables such 
as location advantages for labor costs, lower risks, and the economic health and size of 
local economies (Lampel and Giachetti, 2013). Given offshoring is an antecedent for 
reshoring, reshoring is often understood as simply an extension of strategic offshoring 
decisions (Delis et al., 2017). This suggests that reshoring is viewed as the reverse of 
offshoring. Thus, drivers for reshoring can be barriers for offshoring, and thus 
challenges for reshoring can be motivations for offshoring (Wiesmann et al., 2017). In 
other words, reshoring can be influenced by the original motivation for offshoring. For 
example, the expected benefits of reshoring can be affected by performance and 
consumers, e.g. quality issues and “made-in” effect (Ancarani et al., 2015).  
The original 122 different offshoring and reshoring drivers shown in Appendix 
D are evaluated for commonality and simple semantic differences. This allowed the 
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drivers to be categorized into 63 items using content analysis (Seuring and Gold, 
2012). The content analysis is based on understanding the variables that lead to 
location decisions as suggested by Dunning (1998), which form the conceptual model 
shown in Figure 2. Reshoring drivers under efficiency seeking (ES) advantage are 
conceptually categorized into two factors, cost drivers and performance measures. The 
content analysis revealed that many described the same underlying phenomena, but 
used different terms or different theoretical frameworks without changing the meaning. 
These include both internal and external factors such as labor costs, quality, 
government policy, and host country risks (Kinkel and Maloca, 2009; Vanchan et al., 
2018; Heikkila et al., 2018).  
 Reshoring is also discussed from the perspective of supply chain flexibility and 
resilience, which benefits supplier relationships through better integration (Bailey and 
De Propris, 2014). From the perspective of supply chain risk, offshoring decisions are 
related to product, partner, and environmental characteristics (Schoenherr et al., 2008). 
Studies such as Mihalache and Mihalache (2016) and Di Mauro et al. (2018) identify 
product cost as the most important risk factor to consider in offshoring decisions. They 
find that over the past decade, offshoring is dominated by ES advantages, particularly 
labor cost, followed by resource seeking advantages (RS), such as labor capability and 
process knowledge that are too costly to obtain otherwise. This has led low cost 
countries to engage in aggressive promotion campaigns to attract offshore 
manufacturing (Aspelund and Butsko, 2010). In addition to financial concerns for 
offshoring in developing countries, studies also find that competitive advantages, such 
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as product and process innovation (Lewin et al., 2009) are important ES motivations 
for offshoring decisions. 
Although less dominant, motivations for strategic asset-seeking (SAS) and 
market-seeking (MS) advantages are also important including proximity to customer 
demand (Kinkel, 2012; Ellram et al., 2013), new product development technologies 
(Mohiuddin and Su, 2013), access to local markets, government and regulation 
incentives, quality of human capital, and access to talents (Caniato et al., 2015; Kinkel 
and Maloca, 2009; Vanchan et al., 2018; Heikkila et al., 2018). Roza et al. (2011) 
argue that firm size may create unique strategic objectives for offshoring decisions, 
suggesting that strategies of small firms differ from those of large corporations. For 
example, offshoring decisions for small and large firms may be driven by cost factors, 
while medium-sized firms tend to use offshoring for entrepreneurial drivers that can 
differentiate the firms in the competitive market by, for example, gaining access to 
new markets. 
MacCormack et al. (1994) point out that current cost-based models for 
international manufacturing location decisions are not sustainable because firms 
experience dynamic changes in their external environment. ES advantages that are 
purely cost-driven can vanish quickly based on external changes. With increasing 
automation and enabling technologies such as 3D printing, direct labor costs are less 
emphasized in modern production processes. With less cost pressure, manufacturing 
can move to locations with more SAS advantages. These factors are based on long-
term perspectives such as; 1) high-value activities, 2) availability of tangible and 
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intangible resources in offshored regions, and 3) recovery from offshoring failures and 
changing market situations. 
 
Importance of healthcare-related manufacturing 
Recent government regulation has ratcheted up the pressure on domestic 
production by U.S. medical device and drug manufacturers with concerns about 
soaring drug prices (Rockoff, 2017). As the global healthcare market is rapidly 
growing and expected to reach $10.059 trillion by 2022 (Deloitte, 2019), concerns 
deepen. Healthcare products play an important role in this sense due to their revenue 
generating effect on the economy and direct impact on human well-being.  
 
Table 1. Definitions of medical device and drug (U.S. FDA, 2017; 2019) 
Medical device Pharmaceutical (Drug) 
“...an instrument, apparatus, implement, 
machine, contrivance, implant, in vitro 
reagent, or other similar or related 
article, including a component part, or 
accessory which is: recognized in the 
official National Formulary, or the 
United States Pharmacopoeia, or any 
supplement to them, intended for use in 
the diagnosis of disease or other 
conditions, or in the cure, mitigation, 
treatment, or prevention of disease, in 
man or other animals, or intended to 
affect the structure or any function of 
the body of man or other animals, and 
which does not achieve any of its 
primary intended purposes through 
chemical action within or on the body of 
man or other animals and which is not 
dependent upon being metabolized for 
the achievement of any of its primary 
intended purposes.”  
 
• “A substance recognized by an 
official pharmacopoeia or formulary. 
• A substance intended for use in the 
diagnosis, cure, mitigation, treatment, 
or prevention of disease. 
• A substance (other than food) 
intended to affect the structure or any 
function of the body. 
• A substance intended for use as a 
component of a medicine but not a 
device or a component, part or 
accessory of a device. 
• Biological products are included 
within this definition and are 
generally covered by the same laws 
and regulations, but differences exist 
regarding their manufacturing 




The two dominant product categories in this industry are medical devices and 
pharmaceuticals. As defined by the U.S. Food and Drug Administration (FDA) in 
Table 1, these products directly support healthcare services, and thus, patient care. 
Medical devices and pharmaceuticals are examined in this study because of 
their huge impact on the economy and human life. Unlike other high-tech products 
such as consumer electronics, perceived risks of medical devices and drugs on human 
bodies are relatively high. Medical device and pharmaceutical companies operate in 
different sectors, and specific regulatory frameworks applied on each differ depending 
on the level of risks (i.e. less strict on medical devices). However, both of these two 
industry sectors are required to meet regulations in the product development and 
manufacturing process under FDA control (in the U.S.) due to direct and indirect 
impacts on humans. Additional quality system standards such as ISO 13485 and Good 
Manufacturing Practice (GMP) are demanded by customers in order to meet their high 
quality expectations. High levels of R&D investment are also associated with 
manufacturing medical devices and drugs (Marucheck et al., 2011). 
In previous years, the production and associated supply chains of medical 
device and pharmaceutical manufacturers have increasingly globalized due to low cost 
and favorable regulations in overseas locations such as China (Ni et al., 2017). Rising 
R&D costs and the demand for low cost healthcare encourage firms to move to 
emerging economies to reduce costs (Mohiuddin et al., 2017). Hamdouch and He 
(2009) find that offshoring strategies of medical products significantly lower R&D 
costs through the cost differential between home country and developing regions, such 
as India and China. However, healthcare manufacturers experience challenges created 
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by their offshoring strategy – for example, product quality risk created by a loss of 
control (Gray et al., 2011). The outsourcing of R&D and technology intensive 
processes, such as pharmaceuticals, can result in a higher level of defective products. 
Offshoring creates longer and more complex supply chains with current 
manufacturing processes regulated by manufacturing guidelines to assure safety and 
quality (Chowdary and George, 2012).  
Furthermore, quality risk that impacts safety is higher for these products 
because there is a lag between development, production, and customer use. The issues 
are often not realized until consumers are actually harmed while using the devices or 
drugs. A study by Huq et al. (2016) reports that quality defects remain a major concern 
in the pharmaceutical industry and that the low cost of suppliers may not compensate 
for quality risk. Moser and Montalbano (2018) assert that the number of recall notices 
for Chinese made consumer goods are substantially growing, showing a six times 
higher recall rate than U.S. made products. Thus, these industries require higher levels 
of regulatory restrictions and oversight by the FDA due to their medical use 
(Marucheck et al., 2011). These issues occur due to previous offshoring strategies. 
However, as Grackin (2008) argues, solely cost-based sourcing decisions are not 
appropriate for manufacturing these products. These industry sectors create 
competitive advantage through R&D rather than low skilled and low cost labor that is 
traditionally employed in manufacturing sectors (Silva, 2008).  
The issues of the current offshoring practices raise the importance of 
examining reshoring in the context of healthcare manufacturing. Medical devices and 
pharmaceutical industries have gained increasing importance due to distinct 
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characteristics of high cost and heavily regulated production requirements. Reshoring 
is increasing among medical device manufacturers due to concerns about quality, 
intellectual property, etc., according to the Reshoring Initiative, an organization that is 
dedicated to encouraging reshoring back to the U.S. Despite the high stakes in medical 
devices and drug manufacturing, research on how these reshoring decisions are made 
is sparse. However, understanding reshoring in the context of the healthcare industry 
is critical because of increasing concerns about rising costs of healthcare in many 
countries that affect the sustainability of businesses and social benefits.  
 
Summary of the literature review 
A company’s initial production location decision to offshore manufacturing 
can influence their decision to reshore beyond the loss of expected cost advantages. 
The literature describes a number of other expected benefits including, a) a greater 
proximity to international suppliers and consumers, b) foreign incentives, and c) less 
government regulations in developing economies. These initiatives support all four 
MR, RS, ES, and SAS advantages. However, as the business and political 
environments change, the expected benefits based on the original offshoring 
motivations are reevaluated, leading companies to return production to their home 
country. This study refers to this reevaluation and repositioning of manufacturing 
decisions to meet company objectives as “right-shoring”, which includes either 
offshoring or reshoring, and the right balance of domestic and foreign production.  
From the perspective of sustainability, a company’s objectives must include 
economic, social and environmental performance to be sustainable. In deference to the 
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majority of literature measuring social performance as charity or CSR, this study 
demonstrates that the impact of companies in the healthcare industry can be positive to 
the economy as well as society. Benefits occur through both direct and indirect 
influence on various stakeholders in society who support healthcare to individuals, 
positive corporate profits, and national economic growth. In this sense, reshoring as a 
right-shoring decision in recent years allows firms to consider a broader set of 
variables to achieve company objectives, and thus strengthen corporate sustainability.  
The medical device and pharmaceutical industries have positive impacts on 
economic and social performance due to the importance of the healthcare industry that 
typically pays high salaries while improving human lives. Investment in the foreign 
manufacturing of these products, i.e. offshoring, is dominated by practices focusing on 
cost efficiency. However, over time other important factors appear to be harmed by 
this strategy, or the expected offsets for labor cost are no longer realized that relate to 
market, other resources, and strategic assets. This suggests that motivations to reshore 
may differ from the original objectives of offshoring. This causes firms to reevaluate 
the existing investments to achieve right-shoring. They are willing to consider partial 
or full reshoring to achieve the optimal balance between domestic and foreign 
manufacturing. The OLI framework can explain the conceptual use of right-shoring as 
a decision tool both at an empirical and analytical level. Figure 2 below is a 
conceptual model developed based on the findings from the literature review. The 












The semi-structured interview approach used in this study is recommended 
when the research is still somewhat exploratory and under-researched (Rowley, 2012), 
as in the case of reshoring decisions in healthcare. A theoretical foundation can 
provide structure to properly guide interview questions, but the range of possible 
answers in exploratory studies are not well defined. Twelve interviews were 
conducted in this study, which exceeds the recommended minimum of eight 
respondents, allowing for a thorough qualitative analysis (McCracken, 1988). The 
thoroughness of this type of research is often described as theoretical saturation 
(Robinson, 2014) when no new information is discovered. 
An interview protocol is developed with questions based on the literature 
review and research objectives in line with recommendations by Walker et al. (2008) 
and Kvale and Brinkmann (2009). The procedure for the interview protocol 
development follows Jacob and Furgerson (2012). The interview questions are piloted 
on a professor and a Ph.D. student in the area of operations and supply chain 
management after an iterative review process by the authors. The interview questions 
obtain information on: 
1) demographics of the interviewees and their organizations, 
2) role of quality, regulation, and technology in medical device and drug 
manufacturing, 
3) factors considered in location decisions for healthcare manufacturing, and 
4) how these factors influence reshoring decisions. 
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The interviews are conducted face-to-face and last approximately 30 minutes. 
The interview log is recorded in writing and verified throughout the interview process 
by follow-up questions with the participants. If insufficient information was collected 
due to the interview setting, a follow up phone call or in person meeting was 
conducted for clarification. Nine interviews were conducted at a 2018 annual meeting 
of a medical device manufacturing association which included executives and 
managers. The selected interviewees represent a convenience sample from the 
participants who have expertise in the industry. They include mid to upper level 
management, i.e. senior managers, directors, and CEOs. The interviewees are 
knowledgeable in global sourcing and issues in manufacturing healthcare products due 
to their experience with relevant global companies as well as focal firms and suppliers. 
The organizations represented by the participants have manufacturing facilities located 
in the U.S. and/or overseas (e.g. India, China, Ireland, Sweden, etc.). Three additional 
interviews were conducted outside of the conference on two employees in 
pharmaceutical companies and one in medical device manufacturing, both of which 
are members of large size firms that serve global markets. Descriptive information on 
the interviewees and their organizations is provided in Table 2.  
To avoid misinterpretation and maintain consistency in using the proper 
terminology in this research context, reshoring is defined to the interviewees as 
“moving manufacturing back to the country of its parent company” (Ellram, 2013, p.3). 
While not all twelve organizations have reshored their production, they periodically 
evaluate their domestic and/or foreign manufacturing decisions to ensure that their 
location strategies are still appropriate.  
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Table 2. Descriptive information of interviewees and organizations 






Distributor of medical components 
B Principal Consulting 
Consulting process and quality improvement 
of medical device, pharmaceuticals and other 




Silicone based surgical 
products 
Supplier without R&D;  







Labor expense largest in the total expense, 
serve global market and many global 







Designing, developing and 
manufacturing MedTech 
devices (diagnostics, etc.) 
R&D and manufacturing facilities in India 






Contract manufacturer, serve 70% U.S. 
market and different countries (Malaysia, 
Ireland – specialization), automated 
G CEO Dental supplies 
Small business, labor intensive (manual jobs), 
products only manufactured in the U.S. 
H CEO Medical device sterilizer 
Operate only in the U.S.; provide sterilization 










Global headquarter located in the U.S., a 
















Over the counter and 
prescription drugs 
Global (Ireland, U.S., China, Brazil, Russia, 







Over the counter and 
prescription drugs 
Global consumers, clinical trials, global (40% 
us, 40% EU, others) 
No*: Each alphabet indicates different interviewees from different organizations. 
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Thus, questions particularly relevant to reshoring decisions are based on their 
propensity to reshore. 
 Among the interviewees, five of them are not directly involved in organization 
that manufacture medical devices. Their organizations provide service (i.e. sales and 
distribution) associated with medical devices. However, as CEOs and directors that are 
rather high level decision makers in the relevant industry and members of a medical 
device manufacturing and outsourcing organization, they have a solid understanding 
of manufacturing processes, issues, and relevant decisions in the medical device 
industry through their experience with partners in the supply chain. 
 
Result and discussion 
The results of the twelve interviews reveal important considerations for 
healthcare manufacturing in terms of reshoring decisions. The results find two 
variables that were not found in the literature review. They also emphasize variables 
that are identified as issues of current offshoring strategy in the healthcare 
manufacturing industry – quality and R&D. The findings from the interviews are 
described in the following section and a summary of the individual interview results is 
reported in Appendix F. The results are linked to the four factors of the theoretical 
framework – RS, MS, ES and SAS. 
 
Quality and regulation 
Quality is emphasized as an important factor in manufacturing processes in the 
healthcare industry. Companies in the medical device and pharmaceutical industries 
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particularly strive to achieve high quality of their products and deal with continuing 
safety issues due to their clinical impact on individuals.  
Though achieving high quality in medical products is important, concerns 
about quality issues play a major role in location decisions only if product failures or 
defects occur. This is because foreign plants must go through a qualification process 
prior to being selected as a possible offshoring site. However, the repeated inability of 
a plant to solve its quality issues could result in reshoring. Only one interviewee 
responded, “location matters to quality achievement”. For example, quality issues are 
more likely to occur due to turnover in line-workers or inspectors rather than specific 
location traits. This is the case with regulatory requirements as well. Quality and 
regulation issues are closely related because firms are subject to government 
regulations and industry practices that require compliance with quality system 
standards. According to the World Health Organization (WHO) (2003), regulations for 
quality systems assure that the essential quality requirements are met. Conformity to 
the standards is verified through direct testing and certification. If a company serves 
international markets, it must meet these standards as well as local requirements. The 
Original Equipment Manufacturers (OEMs), suppliers, and contract manufacturers all 
follow these standards because the government and customers expect them to provide 
evidence of the product quality, and in some cases supplier selection guidelines. An 
FDA approval of relevant products as well as a manufacturer is difficult, so regulatory 
satisfaction is also considered an indicator of high quality. While these factors are 
important in production due to potential safety issues, they do not necessarily affect 
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their location decisions. Since the literature discusses quality and regulation as 
decision factors, they are included in the model.  
 
Product specialization and customer requirements 
Location decisions for medical device manufacturers are heavily influenced by 
product specialization. For example, some interviewees explained when production 
involves a high level of customization and specialization, or R&D capabilities, 
companies tend to maintain their manufacturing in home or high-tech locations (e.g. 
U.S., Sweden, Ireland, etc.). For example, among the interviewees, a senior manager 
from Company E with 26 different manufacturing and service locations said that the 
company has its R&D prototyping offshored to Sweden. The company also produces a 
wide range of products for global markets and its manufacturing locations are chosen 
depending on where they can find suppliers and contract manufacturers that are 
willing and able to manufacture what customers want. For the products whose 
manufacturing requirements do not exist in preferred locations, companies must locate 
based on the availability of resources needed for production. For example, Company 
G in the U.S. is a contract manufacturer and has manufacturing facilities located in 
Ireland. Despite Ireland being a costly place for manufacturing and far from the 
company’s home country, products that are needed by its European customers can be 
developed and made in Ireland. Compared to typical consumer goods and other high-
tech products, manufacturing medical devices and pharmaceutical products is highly 
customer driven, due to the effects on human health and relatively short shelf life. 
Thus, firms tend to have fewer options for favorable locations due to the limited 
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availability of manufacturers that specialize in those products. Thus, this implies that 
reshoring can be more attractive to the medical device and pharmaceutical companies 
if the home location has suppliers that have capacity and capability for products in 
their specialization. Customer requirements and markets are viewed as a MS factor, 
while locations that have high-skilled labor to produce customized and specialized 
products are viewed as a RS advantage. 
 
Cost and risks 
Cost is still an important factor for location decisions in both manufacturing 
and R&D, which explains the intense competition in the medical device markets. 
Offshoring can increase risk since less control typically occurs in the product 
development and manufacturing process. This explains how the interviewees 
described the higher likelihood of product failures and product testing costs. Thus, a 
large investment in offshoring R&D and increasing manufacturing costs impacts 
location decisions. To reduce product development and testing costs, firms seek low 
cost regions. For example, Company E designs and manufactures medical devices. 
The company manufactures in India which serves the local customers as well as the 
U.S. market. It is able to reduce costs by also offshoring R&D to India. However, 
while costs are lower, the quality of R&D is impacted. If reshored to the U.S., the 
resulting increase in R&D costs is one of the variables in their relocation decision. 
Seeking lower manufacturing and R&D costs is an ES factor, while countries that 




Product complexity and standardization 
Interviewees uniformly mentioned that the impact of reshoring can depend on 
the type of products. Medical products can be as simple as generic tubes but can be as 
complicated as diagnostic devices. Thus, complexity can involve customization in 
manufacturing processes that impact location decisions. Healthcare companies 
represented in the interviews manufacture a wide range of products, with a small to 
large product volume, serving global customers. Their materials, manufacturing 
processes, the number of off-shored production and suppliers are highly variable. 
Products (especially components, parts, etc.) with low product complexity such as 
simple tubing or silicone bags are still manufactured in low labor cost regions. 
However, production processes that are highly automated for mass production 
can be made in high labor cost regions. However, not all of the participants had highly 
standardized products that can be automated. They produce a variety of products, 
some of which have a high degree of complexity and technological requirements that 
necessitate significant involvement of skilled labor. Low complexity, highly 
standardized products can be made in countries that provide ES advantages. Highly 
complex products requiring more skilled labor or high tech automation are likely in 
countries that can provide resource and supply oriented advantages. 
 
Opportunities and challenges of reshoring decisions 
The interviewees responded that reshoring could benefit their firms by 
providing proximity to customers in their home country (MS), which subsequently 
reduces lead time and transportation costs (ES). Because they recognize that the U.S. 
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has the largest healthcare market in the world, U.S. based medical manufacturing 
companies can benefit from locating closer to market. This allows firms to shorten 
their lengthy supply chain process and logistics costs. The respondent from Company 
D particularly addressed that locating the manufacturing facilities to a home location 
would provide better control for the company. If issues occur in the manufacturing 
process, a prompt response would be possible. Furthermore, according to the manager 
from Company E which manufactures their products in India, customers tend to have 
positive perceptions about “Made-In- USA” products, but only one manager 
mentioned this as a factor in reshoring. Also, access to a skilled workforce is 
recognized as a RS opportunity.  
Reshoring can be beneficial in regard to tariffs for SAS opportunities. One of 
the interviewees mentioned that through their experience manufacturing in China, 
changes in government policies affected tariffs imposed on their products, as they are 
currently experiencing the 2019 trade war between the U.S. and China. If reshored, 
firms can take advantage of favorable policies and stability in regulations. However, 
challenges of reshoring include high market competition and costs that can be higher 
than offshored regions. Especially for a firm that has offshored not only manufacturing 




While the interviewees find a number of benefits and opportunities which can 
motivate them to move their manufacturing back home, none of the interviewed firms 
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have reshored recently. However, if issues such as poor quality occurs from their 
suppliers and contract manufacturers, they will make an effort to improve these issues 
or look for alternative suppliers in the current market. While they are able to still 
leverage manufacturing in low cost countries, the lengthy supply chain can result in 
long lead times. Reshoring is one way to shorten lead time. However, most of the 
interviewees indicate that they serve local customers in the offshored regions in 
addition to the U.S. market. In current strategies that are targeting international 
customers, the benefits of proximity to market from a supply chain perspective do not 
necessarily justify reshoring. Rather, these firms ensure that customers are aware of 
the longer lead times. As demonstrated in the literature, the initial decisions to 
offshore were driven by low labor costs in developing countries. This was also evident 
in the interviews since direct labor costs still make up the largest portion of total costs. 
While reducing costs in manufacturing is important to these firms, they did not see it 
as a consistent, dominating criteria that alone determines location decisions.  
In addition, pharmaceutical manufacturers suggested that existing or growing 
demand in local market, an MS advantage, is a strong motivation for the drugs that 
have to be manufactured where they are sold. The two interviewees from major 
pharmaceutical companies are a small number compared to the number of 
interviewees from medical device manufacturers. However, the potential differences 
in these two industry sectors need further exploration.  
With heavy competition, MS advantages (i.e. the first to introduce a new 
product to the market) are important in selling medical devices and pharmaceuticals. 
In that sense, locating where firms can produce their specialized products can be key 
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to firm performance, which has a greater effect on location decisions. These results 
suggest that current offshored firms in the medical device and pharmaceutical industry 
sectors are more likely to consider reshoring as a SAS decision when the original 
motivation for offshoring no longer exists. New emerging opportunities do not carry 
the same weight in decision-making as maintaining initial expectations. For example, 
they may reshore only if they can no longer satisfy customer-driven requirements in 
the offshored locations. 
Lastly, the result of the semi-structured interview implies potential difference 
in emphasis on decision variables between the two industry sectors. A larger number 
of the interviewees represent medical device manufacturing decisions, which are based 
on cost and quality factors. As one interviewee from the pharmaceutical industry 
suggests, however, “demand in the local market is a critical factor relevant to the 
supply chain decision process”. This may be further investigated through the survey. 
  
Conceptual model 
The results of the interviews are incorporated in the conceptual model from the 
literature review. Based on the interview results, a conceptual model is reviewed and 
revised as shown in Figure 3. Figure 3 shows 65 variables measuring four factors, RS, 
MS, ES, and SAS. The revised conceptual model includes two additional variables, 
product specialization and regulatory requirement which is differentiated regulations 












A survey was developed, pre-tested, pilot-tested, and administered to 
respondents following Dillman’s four step method (2009; 2014). The survey was 
developed based on the research question, the results of the literature review and semi-
structured interviews, and reshoring-related studies that used a survey instrument (i.e. 
Johansson et al., 2018). The initial questionnaire was tested for readability, clarity, 
face validity, and content validity with a group of faculty and Ph.D. students in 
operations and supply chain management that have experience with empirical methods. 
After making several recommended changes, the survey instrument was pre-tested on 
the group of academics again and on 18 business practitioners in an MBA program 
(Pre-test 1). After the survey was refined, the second pre-test was conducted on a 
group of 14 mid-level managers in the pharmaceutical industry in the presence of the 
authors (Pre-test 2). During a group debriefing assessment (Ruel et al., 2016), the 
managers brought up some issues with respect to the number of questions and 
redundancy of the measurement items. A set of questions on reshoring indicators in 
particular was comprised of 65 items, which caused concerns about low response rate 
and overlaps in measurement among the items. Thus, a re-classification through a Q 
sort was recommended and performed with these 14 managers, and then with 17 new 
managers in the medical device industry using a Delphi approach, which reduced the 
reshoring indicators to 35 items. The first round of Q sort reduced 65 items to 54 items; 
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the second round of Delphi study reduced these to 35 items by seeking consensus 
based on 75% threshold (McKnight, 2008).  
The revised instrument was piloted on a group of 16 employees from the 
medical device industry and 14 employees from the pharmaceutical industry (Pilot-
test). The pilot-test group recommended only minor amendments in the survey 
instruction on the first page.  However, there was no substantial change in the 
questions. The responses from the pilot-test are compared with the final survey 
responses for consistency and reliability (Armstrong and Overton, 1977). The final 
questionnaire consists of a total of 14 questions asking background and demographics 
of the survey respondents and their organizations, and 35 items of reshoring factors 
which form 13 variables. Questions on reshoring factors ask to what degree 
respondents agree with each statement using a 5-point Likert scale. The final survey 
instrument is provided in Appendix G. 
 
Reevaluation of the proposed model 
This section explains the Q sort used after Pre-test 2 as a classification method 
(McKnight, 2008) to refine survey items in the model. This process enables a re-
evaluation of identified reshoring indicators in the proposed model and an 
identification of potential correlations among them. Two rounds of Q sort were 
conducted in this process. The first Q sort was conducted with practicing managers of 
Pre-test 2 group in the pharmaceutical industry using a Delphi approach (Brady, 2015). 
The participants were asked to categorize the items into different groups based on 
what each item purports to measure. Sixty-five items were classified into 15 different 
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groups, and those in the 15th group “others” were re-evaluated or removed, resulting in 
reduction of 65 to 54 items. The second round of Q sort was conducted to reach 
consensus on the conceptual classification of the participants. It was conducted on 17 
managers from medical device manufacturers. Corresponding to the threshold of 75% 
consensus by McKnight (2008), items that obtained below 75% agreement were 
dropped. This results in 35 items that measure different reshoring motivations. Details 
on classified items through Q sort are presented in Appendix H, and a refined 
measurement model based on the result is shown in Figure 4. The re-evaluation and 
the refined model provide insights on how managers look at the variables in the 
decision making process. Because of their suggested relationships, first order and 
second order factors are supported in the measurement model. Each measurement item 
for the 13 variables and four factors is described in Appendix H with the Q sort result. 
The re-evaluation also results in the change of cost-related variables to non-ES 
















The survey is delivered online using Qualtrics which is a company that supports 
survey research services such as survey development, data collection (survey 
administration), and data analysis. The survey administration uses two different 
channels:  
1) self-survey administration (participants are verified to work in relevant 
organizations by the researchers) 
2) survey administration through a research firm  
A combination of these two channels overcomes weaknesses underlying each of these 
survey administration approaches. For example, a self-administered survey is 
criticized for its inability to obtain a satisfactory sample size, while a paid survey 
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through a research firm involves a risk of misrepresented qualifications or data due to 
reward motives (Schoenherr et al., 2015). To improve these issues, this study employs 
both approaches. Differences in the survey administration procedures of each 
approach are described in Table 3.  
 
Table 3. Description of survey administration procedures 
 
One issue that occurs with this combined survey administration approach is the 
difficulty in determining a response rate since it occurs through survey research firms. 
Survey invitations are sent to individuals by the authors and the survey firm only 




Survey platform Qualtrics Qualtrics 
Survey method Online Online 
Incentive No incentive Reward pay provided 
Survey invitation N/A 281 (survey accessed) 
Responses collected 137 105 
Data collection 
procedure 
• Survey invitations were 
sent to pre-determined 
respondents. 
• Qualifications of 
respondents were verified 
by their affiliations with 
relevant organizations and 
associations (e.g. 
Association of U.S. 
medical device 
manufacturers) 
• Qualifications based on 
“managers at 
Pharmaceutical/Medical 
Manufacturing firms – 
screened out  “Individual 
Contributor” or “Entry 
Level” 
• An email invitation is sent 
to potential qualified 
respondents in panel 
informing research 
purpose, duration, 




provides information on the number of accessed surveys, which makes it difficult to 
determine a response rate. 
 
Results and discussion 
Sample analysis 
A total of 242 responses were obtained. Sample demographics of the final 
sample of 186 respondents by job experience, firm size, and products are presented in 
Tables 4 – 8 below. Table 4 shows 74.2% of the sample companies that have reshored 
all or part of manufacturing (firm level) and/or are currently considering to reshore. 
Table 5 presents the levels of relevant manufacturing decisions made by the 
respondents in their firms, and the number of job experience in the relevant industry. 
75.8% of the respondents participate in intermediate to very high levels of 
manufacturing related decision making. Table 6 shows the types of products made by 
the companies and firm sizes. Approximately 98% of the companies in the sample 
manufacture medical devices and/or drugs; half of these companies are large firms 
with more than 1000 employees. Table 7 shows the four product characteristics such 
as labor intensity, technology intensity, product standardization (customization), and 
product complexity. Table 8 shows the locations of headquarters and ownership of the 
sample companies. Over 85% of these firms have both ownership and headquarter 
locations in the U.S. The initial sample is explained in Section 4.2.2. A majority of 
participant organizations have reshoring experience or are currently considering 











Table 5. Relevant work experience of the sample respondents 
 
 
Table 6. Product types and firm size of the sample companies 
 
 
Reshoring Frequency Percent 
No reshoring 48 25.8 
Reshored/considering reshoring 138 74.2 
Total 186 100.0 
Decision level Frequency Percent Job Experience Frequency Percent 
None 16 8.6 <1 year 16 8.6 
Very low 10 5.4 1-5 years 38 20.4 
Low 18 9.7 6-10 years 49 26.3 
Intermediate 48 25.8 11-15 years 36 19.4 
Very high 93 50.0 16-20 years 46 24.7 
Total 185 99.5 Total 185 99.5 
N/A 1 .5 N/A 1 .5 
Total 186 100.0 Total 186 100.0 
Product types Frequency Percent Firm size Frequency Percent 
Medical devices only 73 39.2 0-9 employees 2 1.1 
Drugs only 69 37.1 10-49 employees 12 6.5 
Both medical devices and drugs 40 21.5 50-249 employees 29 15.6 
Involved in relevant decision 
making (e.g. sales) 
2 1.1 500-999 employees 46 24.7 
Not involved at all. 1 .5 1000-5000 employees 20 10.8 
Total 185 99.5 5000 or more 76 40.9 
N/A 1 .5 Total 185 99.5 




Table 7. Product characteristics of the sample companies 
 
 
Table 8. Location of headquarters and ownership of the sample companies 
        
Locations 
Headquarter Ownership 
Frequency Percent Frequency Percent 
Non-U.S. 19 10.2 26 14.0 
U.S. 165 88.7 159 85.5 
Total 184 98.9 185 99.5 
N/A 2 1.1 1 .5 
Total 186 100.0 100.0 186 
 
 
Descriptive statistics and data cleaning 
The initial sample of 242 responses is obtained through the online survey and 
subjected to screening for incomplete responses and outliers. The first stage of data 
screening procedure involves an identification of suspect responses that can 
significantly affect data analysis. Of the 242 responses, 2 responses that recorded the 
initiation of the survey but did not have answers were deleted.  
 
 Product standardization Product complexity Tech intensity Labor intensity 
Scale Freq. Percent Freq. Percent Freq. Percent Freq. Percent 
Very low 6 3.2 0 0 18 9.7 4 2.2 
Low 18 9.7 29 15.6 25 13.4 42 22.6 
Moderate 45 24.2 56 30.1 53 28.5 62 33.3 
High 0 0 0 0 0 0 0 0 
Very high 116 62.4 100 53.8 89 47.8 77 41.4 
Total 185 99.5 185 99.5 185 99.5 185 99.5 
N/A 1 .5 1 .5 1 .5 1 .5 




Table 9. Descriptive statistics of the final sample 
Variable Mean Sum Square Deviation Median Range Skewness Kurtosis 
VACSV 2.392 445 348.349 1.372 2 4 0.83 -0.453 
VB1INFRA 4.328 805 212.995 1.073 5 4 -1.233 0.322 
VB2TRANC 3.57 664 375.591 1.425 3 4 -0.293 -1.347 
VC1RAWMA 4.274 795 247.016 1.156 5 4 -1.244 0.282 
VC2PROXS 3.285 611 329.898 1.335 3 4 0.138 -1.267 
VC3CONTM 4.247 790 286.624 1.245 5 4 -1.353 0.524 
VD1ECONS 3.258 606 383.613 1.44 3 4 0.043 -1.391 
VD2CORDC 4.339 807 261.661 1.189 5 4 -1.508 0.919 
VD3PRODC 4.091 761 283.446 1.238 5 4 -0.877 -0.641 
VD4IMPOR 4.253 791 279.124 1.228 5 4 -1.315 0.385 
VD5INVMG 4.161 774 279.161 1.228 5 4 -1.046 -0.272 
VD6FLEXI 2.962 551 312.737 1.3 3 4 0.469 -0.918 
VD7PRODU 4.452 828 208.065 1.061 5 4 -1.741 1.965 
VE1PRODS 3.763 699.848 363.542 1.402 5 4 -0.552 -1.114 
VE2PROXC 3.22 599 423.962 1.514 3 4 0.064 -1.538 
VE3MADEI 3 558 468 1.591 3 4 0.21 -1.543 
VE4LEADT 4.333 806 257.333 1.179 5 4 -1.461 0.769 
VF1POLIR 4.124 767 332.156 1.34 5 4 -1.132 -0.186 
VF2ADMIN 3.78 703 339.962 1.356 5 4 -0.549 -1.006 
VF3REGRE 4.565 849 187.726 1.007 5 4 -2.165 3.52 
VF4GVTSU 4 744 328 1.332 5 4 -0.854 -0.69 
VG1VOLDE 2.409 448 252.946 1.169 2 4 1.035 0.438 
VG2GOVTP 3.78 703 369.962 1.414 5 4 -0.606 -1.038 
VHENVT 2.699 502 277.14 1.224 2 4 0.749 -0.319 
VI1LABOR 4.258 792 303.613 1.281 5 4 -1.388 0.449 
VI2LABOR 3.704 689 378.737 1.431 5 4 -0.437 -1.351 
VJ1CONTC 4.376 814 239.656 1.138 5 4 -1.568 1.212 
VJ2DISTA 2.403 447 278.758 1.228 2 4 0.884 0.049 
VJ3REORG 2.339 435 255.661 1.176 2 4 1.001 0.427 
VK1IP 4.263 793 296.091 1.265 5 4 -1.356 0.332 
VK2SECUR 4.317 803 278.285 1.226 5 4 -1.486 0.778 
VLAUTOMA 3.624 674 375.656 1.425 3 4 -0.307 -1.45 
VNQUALIT 4.468 831 222.306 1.096 5 4 -1.868 2.268 
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VO1RND 2.806 521.988 355.028 1.385 2.494 4 0.509 -0.971 
VO2RNDCO 2.674 497.319 376.667 1.427 2 4 0.632 -0.929 
Then, 16 “straight-liners”, which “occurs when survey respondents give 
identical (or nearly identical) answers to items in a battery of questions using the same 
response scale” (Kim et al., 2019, P. 214), were removed in consideration of their 
effect on data quality. Ten additional responses that were not qualified based on a 
screener question on job level, i.e. individual contributor were dropped. Ten 
disqualified responses are from participants that claimed their affiliated organizations 
did not manufacture medical devices or pharmaceutical products or are not involved in 
relevant decision making. This first stage eliminates 30 responses resulting in 212 
responses. After deleting suspect and/or disqualified responses, a missing value 
analysis is conducted for imputation. Approximately .2% of data points are missing 
and these are imputed using EM imputation method in EQS as EM imputation is 
considered to produce less biased estimates (Musil et al., 2002). Finally, 26 repeated 
outliers, identified as an outliers more than once, are dropped.  
The final sample of 186 responses are included in the analysis. Table 9 
provides descriptive statistics of the final sample. Among 35 reshoring drivers, 
regulatory requirements (V3REGRE) and quality (VNQUALIT) were ranked as the 
top motivation for reshoring decisions, which is consistent with the findings from the 
interviews. 
 
Result and discussion 
Prior to conducting confirmatory factor analysis (CFA), exploratory factor 
analysis (EFA) is conducted for each factor using SPSS to seek the underlying 
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structure of the measurement items (Tokman et al., 2006). The measurement items 
with low correlations are dropped from the factors and the measurement model is 
reconfigured. Table 10 presents the initial 35 items included in EFA.  
 
Table 10. Initial measurement items before EFA 




Availability of qualified personnel 














Control and coordination 
Administration cost 











Proximity to customers 
Made-in effect 
Proximity to suppliers 
R&D cost 




The final measurement model includes four to eight items in each factor with 
the total number of 20 measurement items in the reconfigured model. The result of the 
model fit assessment of the modified model is presented in Table 11. The CFI is .94 
and RMSEA is close to .082, both of which indicate a good fit. The results show a 
good fit of the revised measurement model and the hypothesized relationships between 
measurement items and factors. The detailed model description and coefficient 
estimates of each item and variable are presented in Figure 5. The positive estimates 
suggest positive relations of the variables and the items. The survey results indicate 
the empirical relationship between the variables and factors that affect location 
decisions. However, the contribution of R&D to the SAS is somewhat weaker than 
other variables. This provides an important managerial implication because currently a 
large number of medical devices and pharmaceutical companies still move to countries 
such as China and India for lower R&D costs in addition to manufacturing costs. 
 
Table 11. CFA result fit indices of the measurement model 
Fit indices 
Adjusted chi-square 146.47 
Degrees of freedom 190 
Bentler-Bonett Normed Fit Index (NFI) 0.897 
Comparative fit index (CFI) – Robust 0.940 
Root mean-square error of approximation (RMSEA) – Robust 0.082 
Cronbach’s alpha 0.901 
 
  
The relationship between R&D location and quality issues needs further 
investigation. However, this may suggest that low R&D expenditure in the current 
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offshore region is perceived to be a barrier that impacts economic performance related 
to company share values at the risk of quality problems. The survey results for each 
group, pharmaceutical companies versus medical device companies, were compared 
and presented no significant differences between the groups. 
 






































Prox. to customer 
Made in effect 






























































The findings from this study provides a framework that informs decision-
makers in the medical device and pharmaceutical manufacturing industry. While the 
generalizability of the decision model may be limited because of the contextual focus 
of this study on manufacturing in the healthcare industry, it contributes to the literature 
in two major aspects. First, this study using the four sub-paradigms of the OLI 
framework contributes to the literature by empirically testing the theoretical 
framework to extend the applicability of the theory to business practice. Second, this 
study fills a research gap by providing an industry-specific decision framework that 





















Using the results of the interviews, several parameters are discovered that support 
the development of a rudimentary analytical model with an optimal solution. While an 
empirical investigation of this study finds factors such as quality and regulation as 
important considerations for reshoring decision, the analytical model focuses on the 
difference in the transportation cost and the resulting total cost of a location decision.  
The objective function is the minimization of total costs. This model is considered 
rudimentary because it is the first attempt to develop an optimal right-shoring solution 
based on the available real-world data. It does not claim to be robust because there 
may be other variables that can be included as more information is known. The model 
complements the empirical findings by providing a cost factor, transportation cost, 
which was rather less emphasized in the previous cost-based location decision. While 
this rudimentary analytical model uses the variables found through the literature 
review and interviews, it does not demonstrate the important factors such as quality 
and regulatory issues as a cost differentiator in this model. It is because quality and 
regulatory issues can vary by regions rather than being domestic or foreign. 
 
Objective Function: 
Total cost = {[Annual demand/(Order quantity/Fixed order cost)]/[Unit 
cost*Transportation cost]} + [(Order quantity/2)*Transportation cost] 




d = domestic location (reshoring option) 
f = foreign location (no reshoring option) 
TC = total cost; where TCd is compared to TCf and the location decision is 
based on the lowest total cost. 
D = annual demand (forecast), is uniform across locations 
C = unit cost, varies by location 
FC = fixed order cost, varies by location 
Q = order quantity, is not limited by location 
OF = order frequency, is stated in time units and can vary by location 
T = Transportation cost, is stated as a percentage of C and varies by location 
 
The assumptions of the model are as follows: 
1) Quality: Since quality in reshoring is considered essential, no location will be 
considered that cannot meet minimum quality standards. Therefore, quality is 
treated as a qualifier in this model and thus considered as uniform across all 
possible locations. A quality variable may be represented as a factor in demand 
forecasts by adding a safety stock value to the basic forecast that represents 
additional production need to cover defective goods (or a defect percentage); 
however, none of the interviews shared their quality records so it is not 
included in this model. 
2) Location (L): It is assumed that manufacturers have at least one domestic and 
one foreign location option when considering reshoring. 
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3) Manufacturing: It is assumed that a company controls the manufacturing 
schedule regardless of the locations. This includes a company-owned process 
or a contract manufacturer. 
4) Customer demand (D): It is assumed that customer demand or demand forecast 
is not affected by location. 
5) Inventory: The interviews revealed that drugs and medical devices have short 
shelf lives and thus are shipped just in time. Thus, it is assumed that holding 
costs are uniform across location. 
6) Service levels: Service levels are considered uniform across all locations. The 
interviews revealed that regulators and customers to not tolerate out of stock 
items. Companies will spend more on transportation to prevent late orders and 
stock-outs. 
7) Transportation cost (T): Companies will spend more on transportation to keep 
service levels high. It is often expressed as a function of unit costs in 
managerial accounting. Foreign locations are considered to have higher 
transportation costs than domestic production due to the distance from the 
market (locating to serve the local customers is not considered in the model 
due to variability among manufacturers). 
8) Production: All locations are considered to be available for production for 250 
days per year and 24 hours per day. This accommodates the typical availability 
for developed countries in Europe, Asia, and North America.  
9) Fixed order cost (FC): It can vary by location. 
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10) Order quantity (Q): It can vary but should be based on an optimal quantity 
considering the minimization of transportation and ordering costs. 
 
An example below demonstrates a hypothetical situation of how a firm will decide 
to right-shore based on the analytical model above. It is assumed that: 
1) Quality is equal, comparable labor/technology 2) At least 1 foreign and 1 
domestic option 
3) Contract manufacturing avoids large initial investment 
4) Annual forecast does not depend on location and is stable 
5) No significant inventory holding cost due to JIT 
6) Service levels are equal, transportation costs are the differentiator. 
7) Transportation cost can be represented as a function of C, which represents 
the time differential. 
8) Production days = 250 days/year, 24/5 
9) Foreign location provides lower total manufacturing costs. 
 
1) Total cost of domestic (d) production (TCd) 
TCd = {[1,000,000/(20,000*5,000)]/(100*.25)}+[(20,000/2)*(100*.25)] = 
250,000 
Where: 
Annual forecast (F) = 1,000,000 units 
Unit cost (Cd) = $100/unit 
Fixed cost per order (FCd) = $5,000 
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Order size (Qd) =  = 20,000 units 
Transportation cost (Td) = 25% of unit cost = $25 
Order Frequency = 1 week, minus 2 weeks for holidays = 50 orders/year. 
Orders ship every 5 days. 
 
2) Total cost of foreign (f) production (TCf ) 
TCf= {[1,000,000/(7,071*1,000)]/(40*1.0)}+[(7,071/2)*(40*.1.0)] = 
141,420.10 
Sf=1,000, [1,000,000/(7,071*1,000)]+[(7,071/2)*(40*1)] = 141,420.14 
Sf=5,000, [1,000,000/(7,071*5,000)]+[(7,071/2)*(40*1)] = 141,420.03 
Sf=5,000, [1,000,000/(7,071*5,000)]+[(7,071/2)*(70.71*1)] = 249,995.23 
Where: 
Annual forecast (F) = 1,000,000 units 
Unit cost (Cf) = $40/unit, including customs and tariffs 
Fixed cost per order (FCf) = $1,000 
Order size (Qf) =  = 7,071 units 
Transportation cost (Tf) = 100% of unit cost = $40Order Frequency = 42 hours, 
minus 2 weeks for holidays = 142 orders/year. Orders ship every other day. 
 
3) Right shoring 




This example demonstrates that when the total cost per unit is below $70.71, a 
manufacturer will choose to offshore production. At $70.71 or higher unit cost, a 
manufacturer will choose to reshore. However, foreign production does allow for more 
flexibility with smaller, more frequent ordering. This also implies that with increasing 
labor cost in foreign locations and tariffs imposed upon imported products, firms may 





















This study attempts to develop and empirically test the OLI framework as a 
theoretical grounding that explains the expected benefits of offshoring and reshoring 
in the context of the healthcare manufacturing industry. The literature review 
identified a number of reshoring motivations in the extant literature and found no 
research focusing on a specific industry, particularly in the context of healthcare. In 
spite of the number of articles that attempted to develop an empirically tested 
reshoring decision model, studies were limited to reshoring frameworks based on a 
“one-size-fits-all” approach. As the global healthcare market extensively grows, the 
importance of manufacturing products that support healthcare services has increased. 
In that sense, this study fills the research gap in current reshoring literature by 
examining reshoring motivations of the medical device and pharmaceutical industries. 
A major theoretical contribution is to empirically test the theoretical framework, the 
OLI, which had only been used to conceptually explain and categorize the current 
motivations for location decisions as competitive advantages. The semi-structured 
interviews found the importance of emphasized factors such as quality, regulatory 
requirements, and product specialization on current location decisions.  
The results of the survey find that quality and regulatory requirements 
contribute to current and future reshoring decisions, which is consistent with the 
findings from the literature and interviews. The CFA results suggest that R&D 
capability has a positive but weak relationship with strategic asset advantages that can 
lead to reshoring decisions. This result can be understood in a way that managers in 
the medical device industry and pharmaceutical manufacturers see R&D in offshore 
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regions as an opportunity as opposed to reshoring. Furthermore, this may reflect 
offshoring practices in the medical device and pharmaceutical industries due to the 
availability of R&D outside the home country and even at a lower cost (e.g. India). 
However, this also provides important managerial implications for practicing 
managers. While offshoring for lower R&D costs helps offset rising product costs, 
product recalls according to the FDA continue for various quality issues including 
non-sterility, cracks, leakage, identification of potential safety issues, etc., which may 
potentially lead to a higher cost in the long term. 
Finally, the analytical model in this study incorporates the impact of 
transportation costs and the resulting total cost on estimating parameters that lead to 
optimal right-shoring decisions. The example reflects the current reshoring 
consideration in recent years as firms realize the impact of transportation costs on their 
initial total cost analysis that focused on low labor and manufacturing cost in foreign 
locations. Since the manufacturing cost started increasing in some developing 
economies such as China and the issues from offshoring occurred (e.g. quality), the 
importance of re-evaluating the total cost analysis has been addressed. The model is 
limited in that firms are assumed to have reshoring production as the only alternative 
to foreign production while in reality this may also lead to further offshoring decisions 
to where the total cost estimate is lower. 
The findings of this study make several practical implications. This study 
simplifies the existing reshoring decision frameworks by providing an industry-
specific reshoring model based on the location advantages. Business managers may 
use the model to evaluate and prioritize factors involved in reshoring beyond cost 
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factors. Likewise, policy makers can benefit from this study to understand the factors 
that contribute to reshoring decisions and, thus, to make relevant policies to encourage 
reshoring or discourage offshoring as a way to promote domestic production for 
growth in the local economy. Lastly, this study contributes to sustainability by 
extending the domain of social and economic sustainability to reshoring. It suggests 
that social benefits can be achieved outside of the traditional charitable activities 



















LIMITATION AND FUTURE RESEARCH DIRECTION 
This study makes a contribution to the literature and business practice by 
suggesting an empirically tested reshoring model. However, there are several 
limitations that suggest future research directions.  
First, future research can increase the sample size. The number of responses 
obtained in this study satisfies the recommended sample size for analysis. However, a 
larger sample size can increase the effect size and improve the model fit. Related to 
this, future studies may consider a survey administration approach that provides a 
determinate response rate to improve statistical validity. 
Another future research effort can be made in terms of the scope of the study. 
Even within the same product category, the product complexity varies and 
requirements in the manufacturing process for each type of product can vary. For 
example, among the medical device companies, the level of product complexity varies 
determining labor intensity and ability to automate manufacturing processes. This can 
vary to a greater extent for larger firms that provide a wide range of product lines. 
Further investigation on this matter can be done using field research or in-depth 
interviews.  
Also, the proposed analytical model is limited focusing on the transportation 
cost and resulting total cost as the only differentiator. It is noted that quality and 
regulatory requirements vary by each region rather than by manufacturing in domestic 
country or foreign location. However, future studies can propose an advanced 




Lastly, while this study stresses the need of industry or product specific 
investigation on reshoring decisions, future studies can test the proposed model in 
different contexts. With the criticism on the OLI framework that is considered 
contextual with limited generalizability, the theoretical framework has been mostly 
used for a conceptual understanding of international investment decisions (i.e. Ellram 
et al., 2013; Ancarani et al., 2015). Empirical tests of factors impacting location 
decision as an investment decision can help validate generalizability of the OLI 



















Appendix A. Codification of the systematic literature review (SLR) 
Classification codes 
A Research methodology 
A1 Analytical 
A2 Theoretical (Conceptual) 
A3 Literature review 
A4 Survey 
A5 Case study 
A6 Experiment 
A7 Quantitative (Statistical analysis) 
A8 Interview 
B Research type 
B1 Journal 
B2 Thesis 
B3 Conference proceedings 
B4 White paper 
B5 Industry paper 
C Journal 
C1 Operation Management Research 
C2 Journal of Business Research 
C3 Cambridge Journal of Regions, Economy and Society 
C4 Journal of World Business 
C5 International Journal of Production Economics 
C6 Journal of Manufacturing Technology Management 
C7 Journal of Purchasing & Supply Management 
C8 Journal of Operations Management 
C9 International Journal of Traffic and Transportation Engineering 
C10 Operations and Supply Chain Management 
C11 Growth and Change 
C12 Industrial Marketing Management 
C13 International Journal of Physical Distribution & Logistics Management 
C14 Journal of Engineering Manufacturing 
C15 Management 
C16 International Journal of Production Research 
C17 Supply Chain Forum: An International Journal 
64 
 
C18 Business Horizons 
C19 Manufacturing & Service Operations Management 
C20 International Journal of Management Cases 
C21 Journal of Textile and Apparel, Technology and Management 
C22 International Business and Global Economy 
C23 International Journal of Operations & Production Management 
C24 Journal of the Academy of Marketing Science 
C25 Competition and Change 
C26 Journal of Supply Chain Management 
C27 Strategic Outsourcing: An International Journal 
C28 European Business Review 
E Definition of reshoring 
E1 Home country (backshoring) 
E2 Relocation (reshoring) 
F Context/country 




F5 Single country (regional) 
F6 Multiple countries (international) 
G Reshoring perspective 
G1 Location decision 
G2 Sourcing decision (governance mode) 
G3 Others 
H Reshoring types 
H1 Backshoring for outsourcing 
H2 Backshoring for insourcing 
H3 In house backshoring 
H4 Outsourced backshoring 
H5 Non-backshoring for outsourcing 
H6 Non-backshoring for insourcing 
H7 In house non-backshoring 
H8 Outsourced non-backshoring 
I Research theme 
I1 Reshoring motivations/drivers 
I2 Reshoring decision framework 
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I3 Impact of reshoirng 
I4 Reshoring process 
I5 Impact on reshoring 
J Unit of analysis 




J5 Reshoring volume 
J6 Country 




K3 Document analysis 
K4 Public data 











O Time frame 
O1 Temporal 
O2 Longitudinal 
P Reshoring initiation 
P1 Correction (offshoring failure) 
P2 Reactive decisions 





Appendix B. Result of the systematic literature review (SLR) 
Authors 
Baraldi et al. 
(2018) 
Grappi et al. 
(2018) 
Heikkila et al. 
(2018) 
Stentoft et al. 
(2018) 
Journal C12 C4 C6 C5 
Research 
methodology 
A5 A4, A8 A4 A4, A7 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E1 E1 E1 
Context/Country F2 F1, F2 (Italy) F2 (Finland) F2 (Denmark) 
Reshoring 
perspective 
G1 G1 G1 G1 
Reshoring types H4, partial  n/a n/a n/a (captive or 
insourcing) 
Research theme I4 I3, (demand 
perspective) 
I1 I3 
Unit of analysis J1 I7 J2 J2 
Documentation K2 K1, K2 K1 K1, K4 
Term L1 L1 L5 L5 
Time frame O2 O1 O1 O1 
Reshoring 
initiation 
Strategic change Strategic change 
(value creation) 










Authors Vanchan et al. 
(2018) 
Albertoni et al. 
(2017) 
Brandon-Jones 
et al. (2017) 
Chen & Hu 
(2017) 
Journal C11 C4 C8 C19 
Research 
methodology 
A2 A4 A7 A1 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E2 E1 E1 
Context/Count
ry 
F1, F2 (UK) F6 F1 F1 
Reshoring 
perspective 
G1, G2 G1 G1 G2 
Reshoring 
types 
H2, H3, H4, H8 n/a H1, H2, H3, H4 n/a 
Research 
theme 
I1 I4 I3 I5 
Unit of 
analysis 
J1 J2 J2 J4 
Documentation K6 K4 K4, K5 n/a 
Term L1 L1 L1 L1 
Time frame n/a O2 O2 n/a 
Reshoring 
initiation 
Strategic change Both Strategic change Strategic change 
Healthcare 
(Med device or 
product) 
No  No No 
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Authors Delis et al. 
(2017) 
Gray et al. 
(2017) 
Hartman et al. 
(2017) 
Kim et al. 
(2017) 
Journal C2 C8 C18 C9 
Research 
methodology 
A4 A5 A5 A1 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E1 E1 E1 
Context/Count
ry 
F2, F6  F1 F1 F1 
Reshoring 
perspective 
G1 G1, G2 G1, G2 G1 
Reshoring 
types 
H2, H3 H2, H4 n/a n/a 
Research 
theme 
I1 I1, I2 I2 I3 
Unit of 
analysis 
J2 J3 J4 J5 
Documentation K4 K2 K2 K4 
Term L2 L1 L1, L4 L1 
Time frame O2 O1 O1 O1 
Reshoring 
initiation 













(Med device or 
product) 
  n/a  
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Authors Tate and Bals 
(2017) 
Wiesmann et al. 
(2017) 
Abbasi (2016) Ashby (2016) 
Journal C13 C28 C21 C1 
Research 
methodology 
A2 A3 A2 A5 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E2 E1 E1 E1 
Context/Count
ry 
n/a F2 (Germany) F1 F2 (UK) 
Reshoring 
perspective 
G1, G2 G1 G1 G1, G2 
Reshoring 
types 
H1, H2, H3, H4, 
H5, H6, H7, H8 
n/a (H1, H2, H3, 
H4 – Gray et al. 
(2013)) 
n/a H1, H2, H3, H4 
Research 
theme 
I2 I1 I1 I2, I3 
Unit of 
analysis 
J1  J1 J1 
Documentation K6 K6 K5, K6 K2 
Term L1, L4, L7 L1 L1, L7 L1 
Time frame n/a n/a n/a O2 
Reshoring 
initiation 
Strategic change n/a Strategic change Strategic change 
Healthcare 
(Med device or 
product) 
No n/a No No 
70 
 
Authors Foerstl et al. 
(2016) 





Lavissiere et al. 
(2016) 
Journal C13 C13 C1 C17 
Research 
methodology 
A2 A2 A5 A5 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E2 E1 E1 E1 
Context/Count
ry 







G1 G1 G1 
Reshoring 
types 
H1, H2, H3, H4, 




n/a (H1, H2, H3, 
H4) 
H2, H4, H6, H8 n/a 
Research 
theme 
I1 I1 I2 I5 
Unit of 
analysis 
J2 J1 J1 J3 
Documentation K3, K6 K4, K5, K6 K2 K2 
Term L1 L1 L2, L7 L5 











(Med device or 
product) 
n/a No No No 
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Authors Mlody (2016) Moradlou & 
Backhouse 
(2016) 
Ocicka (2016) Presley et al. 
(2016) 
Journal C22 C14 C15 C17 
Research 
methodology 
A2 A3 A4 A3, A7 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E1 E1 E1 
Context/Count
ry 
F2 F2 (UK) F2 (Poland) n/a 
Reshoring 
perspective 
G1 G1, G2 G1, G2 G1, G2 
Reshoring 
types 
n/a H1, H2, H3, H4 H1, H2, H3, H4 n/a 
Research 
theme 
I1 I1 I1, I3 I2, I4 
Unit of 
analysis 
J6 J3 J3 J1 
Documentation K6 K6 K1 K3, K6 
Term L1 L2 L1 L1 












(Med device or 
product) 
n/a  n/a n/a 
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Authors Robinson & 
Hsieh (2016) 
Srai & Ane 
(2016) 
Stentoft et al. 
(2016a) 
Stentoft et al. 
(2016b) 
Journal C1 C16 C1 C1 
Research 
methodology 
A5 A3 A4, A5 A3 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E1 E1 E1 
Context/Count
ry 
F2 (UK) F2 (UK, France) F2 (Denmark) n/a 
Reshoring 
perspective 
G1 G1 G1, G2 G1 
Reshoring 
types 
H1, H2, H3, H4 
(H2) 
n/a H3 n/a 
Research 
theme 
I3 I1 I1 I1 
Unit of 
analysis 
J1 J1 J1 n/a 
Documentation K2 K6 K1, K2 K6 
Term L1 L1 L5 L5 










(Med device or 
product) 
No n/a  n/a 
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Authors White & 
Borchers (2016) 
Zhai et al. 
(2016) 
Ancarani et al. 
(2015) 
Brennan et al. 
(2015) 
Journal C10 C1 C5 C23 
Research 
methodology 
A4 A7 A7 A2 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E1 E1 E1 
Context/Count
ry 
n/a (F1) F1 F2, F6 F2 (Germany) 
Reshoring 
perspective 
G1 G1 G1, G2 G1 
Reshoring 
types 
n/a H1, H2, H3, H4 n/a n/a (H2, H4) 
Research 
theme 
I1, I2 I1, I5 I1 I1, I5 
Unit of 
analysis 
J1 J1 J1 J1 
Documentation K1 K4, K5 K5 K6 
Term L1 L1 L1 L2, L5 
Time frame O1 O2 O2 n/a 
Reshoring 
initiation 






(Med device or 
product) 
No No n/a No 
74 
 
Authors Grappi et al. 
(2015) 





Bailey & De 
Propris (2014) 
Journal C24 C5 C7 C3 
Research 
methodology 
A6 A5 (action 
research) 
 A2 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E1  E2 
Context/Count
ry 
F2(Italy) F2 (Finland) F2 (Denmark) F1, F2 (UK) 
Reshoring 
perspective 
G1 G1  G1 
Reshoring 
types 




 H1, H2, H3, H4 
Research 
theme 





J7 J3  J2 
Documentation K1, K2 n/a (K2)  K5, K6 
Term L1 L5 L5 L1 






Strategic change n/a Strategic change 
Healthcare 
(Med device or 
product) 
No No n/a No 
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Authors Bailey & De 
Propris (2014) 
Fratocchi et al. 
(2014) 
Kinkel (2014) Martinez-Mora 
& Merino 
(2014) 
Journal C3 C7 C7 C7 
Research 
methodology 
A2 A2 A4 A8/A5 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
E1 E2 E1 E2 
Context/Count
ry 
F2 (UK) n/a F2 (Germany) F2 (Spain) 
Reshoring 
perspective 
 G1 G1, G2 G1 
Reshoring 
types 
  H1, H2, H3, H4 
(exit mode only 
– not specified 
reshoring 
modes) 












  J2 J2 
Documentation K2, K6 K6 K4 K2 
Term L1 L8 L5 L1 













(Med device or 
product) 











Journal C25 C7 C18 C27 
Research 
methodology 
A2  A4 A4 
Research type B1 B1 B1 B1 
Definition of 
reshoring 
  E2 E1 
Context/Count
ry 




  G1 G1 
Reshoring 
types 
  n/a n/a  
Research 
theme 
I3 I1 I1 I1, I5 
Unit of 
analysis 
  J2 J2 
Documentation K6  K1 K1 
Term L5  L! L5 
Time frame O1  O1 O1 
Reshoring 
initiation 
  Reactive 
decisions 




(Med device or 
product) 






Ellram et al. 
(2013) 







Journal C26 C26 C26 C23 C7 
Research 
methodology 
 A4 A2 A4, A7 A4 
Research type B1 B1 B1 B1 B1 
Definition of 
reshoring 











 G1 G1 G1, G2 G1 
Reshoring 
types 
 n/a (owned 
manufacturi
ng facilities) 
H1, H2, H3, 
H4 
n/a (H1, H2, 
H3, H4, H5, 




Editorial I1 I4 I1 I1 
Unit of 
analysis 
 J2 J2 J2 J2 
Documentation  K1 K6 K4 K1, K4 
Term  L1, L4 L1 L5 L5 












(Med device or 
product) 




































































































































Kinkel & Maloca (2009) V V V V V 
Kinkel (2012) V V V V V 
Canham & Hamilton (2013)      
Bailey & De Propris (2014a)      
Bailey & De Propris (2014b)      
Kinkel (2014)      
Martinez-Mora & Merino (2014)  V    
Mezzadri (2014)  V    
Tate et al. (2014) V V    
Ancarani et al. (2015)      
Brennan et al. (2015)      
Gylling et al. (2015)      
Abbasi (2016)  V    
Ashby (2016)  V    
Foerstl et al. (2016)      
Fratocchi et al. (2016) V V    
Joubioux & Vanpouke (2016)      
Ocicka (2016)  V    
Robinson & Hsieh (2016)  V    
Stentoft et al. (2016a)      
Zhai et al. (2016) V V V   
Albertoni et al. (2017)      
Brandon-Jones et al. (2017)  V   V 
Chen & Hu (2017)      
Delis et al. (2017) V V V V V 
Gray et al. (2017)  V    
Hartman et al. (2017)      
Kim et al. (2017) V V V   
Baraldi et al. (2018)  V    
Heikkila et al. (2018) V V V V  
Johansson & Olhager (2018) V  V V  
Johansson et al. (2018) V  V V  



















































































































Kinkel & Maloca (2009) V V V V V 
Kinkel (2012) V V V V V 
Canham & Hamilton (2013)      
Bailey & De Propris (2014a)      
Bailey & De Propris (2014b)      
Kinkel (2014)    V  
Martinez-Mora & Merino (2014)      
Mezzadri (2014)      
Tate et al. (2014) V    V 
Ancarani et al. (2015)      
Brennan et al. (2015)    V  
Gylling et al. (2015)      
Abbasi (2016)      
Ashby (2016)      
Foerstl et al. (2016)      
Fratocchi et al. (2016)      
Joubioux & Vanpouke (2016)      
Ocicka (2016) V     
Robinson & Hsieh (2016)      
Stentoft et al. (2016a)      
Zhai et al. (2016) V  V V  
Albertoni et al. (2017)      
Brandon-Jones et al. (2017) V V   V 
Chen & Hu (2017)      
Delis et al. (2017) V V V V V 
Gray et al. (2017)    V  
Hartman et al. (2017)      
Kim et al. (2017)    V V 
Baraldi et al. (2018)      
Heikkila et al. (2018) V V V  V 
Johansson & Olhager (2018) V V  V V 
Johansson et al. (2018) V V V V V 









































































































































Kinkel & Maloca (2009) V V V V V 
Kinkel (2012) V V V V V 
Canham & Hamilton (2013)      
Bailey & De Propris (2014a)      
Bailey & De Propris (2014b)      
Kinkel (2014) V     
Martinez-Mora & Merino (2014)      
Mezzadri (2014)      
Tate et al. (2014) V V V   
Ancarani et al. (2015) V     
Brennan et al. (2015) V     
Gylling et al. (2015)    V  
Abbasi (2016)      
Ashby (2016)      
Foerstl et al. (2016)      
Fratocchi et al. (2016) V    V 
Joubioux & Vanpouke (2016)      
Ocicka (2016)     V 
Robinson & Hsieh (2016)      
Stentoft et al. (2016a)      
Zhai et al. (2016)   V   
Albertoni et al. (2017)      
Brandon-Jones et al. (2017) V   V V 
Chen & Hu (2017)      
Delis et al. (2017) V   V V 
Gray et al. (2017)    V  
Hartman et al. (2017)      
Kim et al. (2017) V V  V  
Baraldi et al. (2018)      
Heikkila et al. (2018)   V V V 
Johansson & Olhager (2018) V V    
Johansson et al. (2018) V V V V  
















































































Kinkel & Maloca (2009)         
Kinkel (2012)         
Canham & Hamilton (2013) V V       
Bailey & De Propris (2014a)   V      
Bailey & De Propris (2014b)   V      
Kinkel (2014)         
Martinez-Mora & Merino (2014)         
Mezzadri (2014)         
Tate et al. (2014)   V V V V V V 
Ancarani et al. (2015)   V      
Brennan et al. (2015)         
Gylling et al. (2015)         
Abbasi (2016)         
Ashby (2016)         
Foerstl et al. (2016)         
Fratocchi et al. (2016)   V     V 
Joubioux & Vanpouke (2016)    V     
Ocicka (2016)   V      
Robinson & Hsieh (2016)         
Stentoft et al. (2016a)       V  
Zhai et al. (2016)         
Albertoni et al. (2017)      V   
Brandon-Jones et al. (2017)      V   
Chen & Hu (2017)         
Delis et al. (2017)     V   V 
Gray et al. (2017)         
Hartman et al. (2017)         
Kim et al. (2017)        V 
Baraldi et al. (2018)         
Heikkila et al. (2018)   V  V   V 
Johansson & Olhager (2018)   V     V 
Johansson et al. (2018)   V      

















































































































Kinkel & Maloca (2009)        
Kinkel (2012)        
Canham & Hamilton (2013)        
Bailey & De Propris (2014a)        
Bailey & De Propris (2014b)        
Kinkel (2014)        
Martinez-Mora & Merino (2014)        
Mezzadri (2014)        
Tate et al. (2014)        
Ancarani et al. (2015)        
Brennan et al. (2015)        
Gylling et al. (2015)        
Abbasi (2016)        
Ashby (2016)        
Foerstl et al. (2016)        
Fratocchi et al. (2016) V V V V   V 
Joubioux & Vanpouke (2016)        
Ocicka (2016)  V      
Robinson & Hsieh (2016)        
Stentoft et al. (2016a)        
Zhai et al. (2016)  V   V   
Albertoni et al. (2017)        
Brandon-Jones et al. (2017)        
Chen & Hu (2017)        
Delis et al. (2017)      V  
Gray et al. (2017)     V   
Hartman et al. (2017)        
Kim et al. (2017) V       
Baraldi et al. (2018)        
Heikkila et al. (2018)      V  
Johansson & Olhager (2018)        
Johansson et al. (2018)        
Vanchan et al. (2018)  V     V 
*References with no industry focus are excluded in the table. 
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Appendix D. Reshoring drivers in the literature 
No. Factors Citations and References 
1 Flexibility 
Kinkel & Maloca (2009), Kinkel (2012), Canham & 
Hamilton (2013), Kinkel (2014), Brennan et al. 
(2015), Gylling et al. (2015), Fratocchi et al. (2016), 
Robinson & Hsieh (2016), Stentoft et al. (2016a), 
Stentoft et al. (2016b) 
2 Quality 
Kinkel & Maloca (2009), Kinkel (2012), Canham & 
Hamilton (2013), Gray et al. (2013), Arlbjorn & 
Mikkelsen (2014), Bailey & De Propris (2014a), 
Bailey & De Propris (2014b), Kinkel (2014), 
Ancarani et al. (2015), Brennan et al. (2015), Gylling 
et al. (2015), Fratocchi et al. (2016), Joubioux & 
Vanpouke (2016), Mlody (2016), Moradlou & 
Backhouse (2016), Presley et al. (2016), Stentoft et 
al. (2016a), Stentoft et al. (2016b) Zhai et al. (2016) 
3 Coordination cost 
Kinkel & Maloca (2009), Kinkel (2012), Canham & 
Hamilton (2013), Brennan et al. (2015), Mlody 
(2016), Moradlou & Backhouse (2016), Robinson & 
Hsieh (2016), Stentoft et al. (2016a) 
4 Infrastructure 
Kinkel & Maloca (2009), Brennan et al. (2015), 
Mlody (2016), Srai & Ane (2016) 
5 
Availability of qualified 
personnel 
Kinkel & Maloca (2009), Kinkel (2012), Canham & 
Hamilton (2013), Kinkel (2014), Tate et al. (2014), 
Brennan et al. (2015), Fratocchi et al. (2016), Srai & 
Ane (2016), Stentoft et al. (2016a), White & 
Borchers (2016), Zhai et al. (2016), Albertoni et al. 
(2016) 
6 Ability to deliver on time 
Kinkel (2012), Canham & Hamilton (2013), 
Martinez-Mora & Merino (2014), Ancarani et al. 
(2015), Brennan et al. (2015), Fratocchi et al. (2016) 
7 Labor cost 
Kinkel (2012), Canham & Hamilton (2013), Ellram 
et al. (2013), Bailey & De Propris (2014a), Kinkel 
(2014), Tate (2014), Tate et al. (2014), Fratocchi et 
al. (2016), Mlody (2016), Moradlou & Backhoue 
(2016), Ocicka (2016), Robinson & Hsieh (2016), 
Srai & Ane (2016), Stentoft et al. (2016a), White & 
Borchers (2016), Zhai et al. (2016) 
8 Monitoring cost Kinkel (2012), Brennan et al. (2015) 
9 Communication cost Canham & Hamilton (2013), Srai & Ane (2016) 
10 Logistics 
Ellram et al. (2013), Bailey & De Propris (2014b), 
White & Borchers (2016) 
11 Switching cost Ellram et al. (2013), White & Borchers (2016) 
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12 Raw material 









Ellram et al. (2013), Presley et al. (2016), Srai & 
Ane (2016), White & Borchers (2016) 
14 
Government trade 
policies (tax, trade 
requirements) 
Ellram et al. (2013) Joubioux & Vanpouke  (2016) 
Srai & Ane (2016) – political stability, natural 
disaster White & Borchers (2016) 
15 Tax rates Gray et al. (2013), Tate et al. (2014) 
16 Tariffs Gray et al. (2013), Stentoft at al. (2016a) 
17 Currency exchange 
Ellram et al. (2013), Gray et al. (2013), Bailey & De 
Propris (2014a), Tate et al. (2014), Joubioux & 
Vanpouke (2016), Mlody (2016), Moradlou & 
Backhoue (2016), Ocicka (2016), Srai & Ane (2016), 
White & Borchers (2016) 




Gray et al. (2013), Tate (2014), Mlody (2016) -  
cultural Robinson & Hsieh (2016), Srai & Ane 
(2016) – psychic 
20 Lead time 
Arlbjorn & Mikkelsen (2014), Tate et al. (2014), 
Joubioux & Vanpouke (2016), Robinson & Hsieh 
(2016), Zhai et al. (2016) 
21 Automation 
Arlbjorn & Mikkelsen (2014), Tate (2014), Mlody 
(2016), Srai & Ane (2016), Stentoft et al. (2016a), 
Stentoft et al. (2016b), Zhai et al. (2016) 
22 Focus on core activities Arlbjorn & Mikkelsen (2014), Stentoft et al. (2016a) 
23 R&D 
Arlbjorn & Mikkelsen (2014), Kinkel (2014), 
Brennan et al. (2015), Ashby (2016), Joubioux & 
Vanpouke (2016), Robinson & Hsieh (2016), Srai & 




Bailey & De Propris (2014a), Kinkel (2014), Tate et 
al. (2014), Brennan et al. (2015), Fratocchi et al. 
(2016), Ocicka (2016), Robinson & Hsieh (2016), 





Bailey & De Propris (2014a), Bailey & De Propris 
(2014b), Joubioux & Vanpouke (2016), Presley et al. 
(2016), Srai & Ane (2016), Stentoft et al. (2016a), 
Wiesmann et al. (2017) 
26 Cost (total) Bailey & De Propris (2014b), Tate (2014), Ancarani 
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et al. (2015), Abbasi (2016), Fratocchi et al. (2016), 
Ocicka (2016), Robinson & Hsieh (2016), Stentoft et 
al. (2016b), Zhai et al. (2016), Albertoni et al. 
(2017), Kim et al. (2017) 
27 Skilled workforce 
Bailey & De Propris (2014b), Joubioux & Vanpouke 
(2016) 
28 Responses to customers Bailey & De Propris (2014b), Tate (2014) 
29 Technology 
Bailey & De Propris (2014b), Gylling et al. (2015), 
Ocicka (2016), Srai & Ane (2016) 
30 Operations cost Bailey & De Propris (2014b) 
31 (Customer) services 
Bailey & De Propris (2014b), Ancarani et al. (2015), 
Fratocchi et al. (2016), Srai & Ane (2016) 
32 Innovation 
Bailey & De Propris (2014b), Tate (2014), Fratocchi 
et al. (2016), Joubioux & Vanpouke (2016), Mlody 
(2016), Robinson & Hsieh (2016), Albertoni et al. 
(2017) 
33 Turnover Bailey & De Propris (2014b) 
34 Coordination Kinkel (2014) 
35 Know-how 
Kinkel (2014), Brennan et al. (2015), Srai & Ane 
(2016), Stentoft et al. (2016a) 
36 Proximity to home Kinkel (2014) 
37 
Increase in domestic 
production 
(replenishments) 
Martinez-Mora & Merino (2014) 
38 Increase in new products Martinez-Mora & Merino (2014) 
39 Failure in market 
Martinez-Mora & Merino (2014), Foerstl et al. 
(2016), Albertoni et al. (2017) 







Tate (2014), Mlody (2016), Moradlou & Backhouse 
(2016), Srai & Ane (2016), Stentoft et al. (2016a) 
43 IP protection (risk) 
Tate (2014), Fratocchi et al. (2016), Joubioux & 
Vanpouke (2016), Mlody (2016), Moradlou & 
Backhouse (2016), Ocicka (2016), Stentoft et al. 
(2016a), Zhai et al. (2016) 
44 Shipping requirement Tate (2014) 
45 Energy cost 
Tate (2014), Tate et al. (2014), Moradlou & 
Backhouse (2016), Ocicka (2016) 
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Tate et al. (2014), Mlody (2016), Moradlou & 
Backhouse (2016) 
48 Proximity to customers 
Tate et al. (2014), Ancarani et al. (2015), Fratocchi 
et al. (2016), Mlody (2016), Srai & Ane (2016), 
Stentoft et al. (2016a) 
49 Made in effect 
Ancarani et al. (2015), Fratocchi et al. (2016), Mlody 
(2016), Stentoft et al. (2016a) 
50 Government incentives 
Ancarani et al. (2015), Stentoft et al. (2016a), Zhai et 
al. (2016) 
51 Capacity utilization Brennan et al. (2015), Fratocchi et al. (2016) 
52 Import cost Gylling et al. (2015) 
53 Production cost Gylling et al. (2015), Mlody (2016) 





Gylling et al. (2015), Stentoft et al. (2016a) 




Gylling et al. (2015) 
58 Growth of local economy Ashby (2016) 




Forestl et al. (2016) 
61 Relational issues Forestl et al. (2016) 
62 Asset specificity Forestl et al. (2016) 
63 Reorganization Fratocchi et al. (2016) 
64 Cost efficiency Fratocchi et al. (2016) 
65 
Termination of supply 
relationships 
Fratocchi et al. (2016) 
66 Minimum order size Fratocchi et al. (2016) 
67 Control complexity Fratocchi et al. (2016), Zhai et al. (2016) 
68 Subsides for relocation Fratocchi et al. (2016) 
69 
Lack of local market 
attractiveness 
Fratocchi et al. (2016) 




Absence of local 
suppliers 
Fratocchi et al. (2016) 
72 
Customer duties for re-
import 
Fratocchi et al. (2016) 
73 
Unions’ pressure at the 
home country 
Fratocchi et al. (2016) 
74 
Adaptation to customer 
needs & reliability 
Joubioux & Vanpouke (2016) 





77 Investment incentives Mlody (2016) 
78 Proximity to market Mlody (2016), Srai & Ane (2016) 
79 Control cost Mlody (2016), Robinson & Hsieh (2016) 
80 Supply chain risk 
Mlody (2016), Stentoft et al. (2016a), White & 
Bochers (2016) 
81 Inventory 
Moradlou & Backhouse (2016), Srai & Ane (2016), 
Zhai et al. (2016) 
82 (extra) Management 
Moradlou & Backhouse (2016), Stentoft et al. 
(2016b) 




Moradlou & Backhouse (2016) 
85 Communication Moradlou & Backhouse (2016) 
86 (Inter) cultural difference Moradlou & Backhouse (2016) 
87 Language barrier Moradlou & Backhouse (2016) 
88 Supply chain relationship Ocicka (2016) 
89 Environmental concern 
Ocicka (2016), Presley et al. (2016), Srai & Ane 
(2016), Zhai et al. (2016) 
90 Lean supply chain Ocicka (2016) 
91 Supply chain disruption Ocicka (2016) 
92 NPV Presley et al. (2016) 
93 Company share value Presley et al. (2016) 
94 Coordination Presley et al. (2016) 
95 Reputation/image/brand Presley et al. (2016), Zhai et al. (2016) 
96 Local incentives Srai & Ane (2016) 
88 
 
97 Relationships/network Srai & Ane (2016) 
98 Economies of scale Srai & Ane (2016) 
99 Security Srai & Ane (2016), Stentoft et al. (2016b) 
100 Contract terms Srai & Ane (2016) 
101 Raw material cost Srai & Ane (2016) 
102 Administrative cost Srai & Ane (2016) 




Srai & Ane (2016) 
105 Hidden cost Srai & Ane (2016) 
106 Vertical integration Srai & Ane (2016) 
107 
Location branding for 
traceability of the product 
Srai & Ane (2016) 
108 
Location branding for 
quality image 
Srai & Ane (2016) 
109 
Location branding for 
local social impact 
Srai & Ane (2016) 
110 
Better traceability of 
products 
Srai & Ane (2016) 
111 Actual cost Stentoft et al. (2016a) 
112 
Production and delivery 
reliability 
Stentoft et al. (2016a) 
113 Shrinking market size Stentoft et al. (2016a) 
114 Patriotism/loyalty Stentoft et al. (2016a) 
115 
Correction of misjudged 
decision 
Stentoft et al. (2016a) 
116 Bureaucracy Stentoft et al. (2016b) 
117 Production basis Stentoft et al. (2016b) 
118 Strategic access White & Borchers (2016) 
119 Response to demand Zhai et al. (2016) 
120 Lean manufacturing Zhai et al. (2016) 
121 
Firm specific locational 
advantage 
Delis et al. (2017) 
122 Global competition Wiesmann et al. (2017) 
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Appendix E. Codification of the interview responses 
No. Q3 Q4 Q5 Q6 
A 




- Quality and 
regulation often go 
hand in hand 
 - Regulation 
designed to force 
product to be 
required quality 
level 
- Technology varies 
- Availability of raw 
materials 
- Environment 
- Quality is most 
important 
- These do not 
impact much 
B 
n/a - Quality and 
regulation are 
important and need 
simultaneously 
- Technology can 
differ from company 
to company 
- Availability of raw 
material 
- Skilled workforce 
- Regulatory assessment 
process 
- Environment 





- It varies product 
to product 
- Regulation has 
more impact 
because it forces to 
meet the minimum 
quality level 







n/a - Technology 
depends on the 
complexity of 
products 












depends on products 
- Cost 
- Tariffs (e.g. China) 








- Quality and 
regulation especially 
impact a lot on 
manufacturing 
process 
- R&D cost 
- Labor cost does not 
impact a lot 






n/a - Quality matters 
more than low labor 
cost 
- Availability and cost of 
labor 
- It impact net 
profit 
H 
n/a - Quality matters; 
regulation is 
required 











- Safety and 
effectiveness 
- Quality, regulation, 
and technology all 
have big impact on 
firm performance 




and after use by 
FDA and other 
country 
requirements 
- Cost (affordability – 
price) 
- Cost, quality, 
regulation, and 
technology together 
- Proximity to 
R&D 





















- Quality and 
regulation have 
more impact than 
technology 
- Raw materials - Technology 
- Tax 
incentive 




- Impact on 
human being and 
safety 
- Quality and 
regulation are highly 
important e.g. 
manufacturing 
facilities in Europe 
are investigated and 
highly regulated by 
EU 
- Technology is 
needed to the extent 
it is sufficient to 
manufacturing 
products 













(drugs) are sold 
in the location 
that is approved 
by healthcare 
authority country 




- Quality is the most 
important and 
placed based on 
customer demand 
- Technology is easy 
to transfer over the 
borders 




























- Location matters to 
firm performance 
due to regulatory 
process 
With offshoring 
- IP protection issues, 
R&D in developing 
economy (e.g. India) does 





n/a - Impact on product 
quality 







- Quality does not 
have so much 
impact on the 
location decision 





- Longer lead time 
specified to customers, 
With reshoring 






- Factors are 






- Cost - Location does not 
impact a lot 
With offshoring 
- Currently not so much 





- R&D cost 
- Location impacts 






- Not so much of quality 
issues because of the 









- Location does not 
impact a lot 
With reshoring (domestic 
operations) 
- Obtaining high quality 
and low cost labor is 
difficult 
- Quality 
- Low labor 
cost 
H 
 - Impact on 
employee turnover 
rate 
With offshoring and 
reshoring, 





- Labor cost 
I 
- Supply chain 
- Cost 
- Impact on 
productivity – cost, 
quality, product, and 
With reshoring 
- Business continuity 





profit - Better customer 
perception 






- Minimal impact on 
firm performance 
- Can impact in 




language barrier and time 
difference 
- Expertise 
- Regulatory process  
With reshoring 
- Less communication 
issue 
- Better control 
- Better regulatory 







- Quality - Impact on the 
supply chain 
With offshoring 
- Being able to work with 
government agencies e.g. 
China 
- Regulations are not 
clear or established in 
some locations 
With reshoring 
- Expertise is increased 
- Reliability and 
familiarity 
- Better oversight 
- Less quality concern 
- Better security 
- May lack production 
capacity 








- Impact on cost 
performance 
because drug prices 
are fixed by the 
government in some 
countries 
With offshoring 
- Availability and low 
cost of raw material 
- Increasing demand 
- Low cost operation sites 
With reshoring 
- Rising demand in 
neighboring countries e.g. 
Canada, Mexico 
- Tax benefits 
- Import and export cost 
- Increasing operating 
cost  
- Challenges to meet 






Appendix F. Interview questions 
1) Background (job title) 
2) Company background (industry, primary products, etc.) 
3) What are the distinct characteristics of medical devices or drugs compared to 
other manufacturing industry sectors (e.g. automotive)? 
4) How do quality, regulation, and technology impact decisions made in the 
manufacturing process? 
a. What is the regulation(s) that your company particularly has to deal 
with if there is any?  
5) What other factors affect medical device or drug manufacturing? 
6) What are the roles of these factors in manufacturing location decision? 
7) What are the factors considered the most and least important in this decision 
and why? 
8) How does manufacturing location impact on product or firm performance? 
9) If currently offshored, what are the primary opportunities and/or challenges in 
the current location and home country? 














Appendix G. Survey questions 
1. Has your company reshored from the previous offshored region(s)? 
a) Yes 
b) No 
c) I don’t know 





c) I don’t know 
3. What is your job title in the company? 
 
_______________________________________ 
4. Which of the following best describes your level in the company? 
a) Owner/Director/CEO 
b) Upper management (President, Vice president, etc.) 
c) Middle management 
d) Lower management/Supervisory 
e) Technical 
5. To what level do you participate in manufacturing decision making of your 
company? 
 
a) None    b) Very low    c) Low    d) Intermediate    e) High    f) Very high 
6. How many years of job experience do you have in the industry? 
a) Less than 1 year 
b) 1 – 5 years 
c) 6 – 10 years 
d) 11 – 15 years 
e) 16 – 20 years 
f) 20 years or more 
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7. Does your company manufacture medical devices or drugs? 
a) Medical devices only  
b) Drugs and other pharmaceutical products only 
c) Both medical devices and drugs  
d) I don’t know 
e) No, but we are involved in decision making related to manufacturing these 
products (e.g. sales). 
f) No, we are not involved in any of these products. 
8. Please rate the following product characteristics of the primary product(s) 
produced by your company. 
 
Product complexity a) very low  b) low  c) moderate  d) high  e) very high 
Product standardization a) very low  b) low  c) moderate  d) high  e) very high 
Technology intensity a) very low  b) low  c) moderate  d) high  e) very high 
Labor intensity a) very low  b) low  c) moderate  d) high  e) very high 
9. Where does your company manufacture product(s)? Select all that apply. 
a) U.S. 
b) North America (non-U.S.) 




g) Others (Please specify.) ______________________ 
10. Where is the majority of your product(s) sold? 
a) U.S. 
b) North America (non-U.S.) 






g) Others (Please specify.) ______________________ 
11. What is the country where your company headquarters are located?  
a) U.S. 
b) Others (Please specify.) ____________________ 
12. What is the country of ownership of your company (home country)? 
a) U.S. 
b) Others (Please specify.) ____________________ 
13. What is the total number of employees in your company? 
a) 0 – 9 employees 
b) 10 – 49 employees 
c) 50 – 249 employees 
d) 250 – 499 employees 
e) 500 – 999 employees 
f) 1000 – 5000 employees 
g) 5000 or more employees 
14. Following are about factors that are involved in reshoring decisions. Please 





Low Moderate High 
Very 
high 
Company share value 1 2 3 4 5 
Infrastructure (e.g. transportation, logistics, 
information systems, etc.) 
1 2 3 4 5 
Transportation cost 1 2 3 4 5 
Availability of raw materials 1 2 3 4 5 
Proximity to suppliers 1 2 3 4 5 
Ability to manage contract manufacturers 
in offshored location(s) 
1 2 3 4 5 
Economies of scale (cost advantage 
through a large volume of production) 
1 2 3 4 5 
Coordination and communication cost to 
process information from/to manufacturing 
in offshored location(s) 
1 2 3 4 5 
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Production cost (except labor) with 
manufacturing in offshored location(s) 
1 2 3 4 5 
Import cost to/from offshored location(s) 1 2 3 4 5 
Inventory management 1 2 3 4 5 
Flexibility in manufacturing 1 2 3 4 5 
Productivity 1 2 3 4 5 
Level of product specialization 1 2 3 4 5 
Proximity to market or customers 1 2 3 4 5 
Customer perception of “Made in” home 
country (e.g. USA) products 
1 2 3 4 5 
Lead time 1 2 3 4 5 
Political risk (e.g. instability, regime 
change, etc.) in offshored location(s) 
1 2 3 4 5 
Administrative conditions and cost in 
offshored locations 
1 2 3 4 5 
Regulatory requirement for products 
imported to or sold in home country (e.g. 
FDA) 
1 2 3 4 5 
Government subsidies for relocation 1 2 3 4 5 
Reponses to volatile demand in home 
country 
1 2 3 4 5 
Government pressure to voluntarily 
produce goods in home country 
1 2 3 4 5 
Environmental concerns (e.g. pollution) in 
offshored location(s) 
1 2 3 4 5 
Supply chain disruptions 1 2 3 4 5 
Lack of qualified labor in offshored 
location(s) 
1 2 3 4 5 
Labor cost in offshored location(s) 1 2 3 4 5 
Ability to control and coordinate with 
manufacturing 
1 2 3 4 5 
Distance (physical distance and/or 
perceived difference) with offshored 
location(s) 
1 2 3 4 5 
Reorganization of the company (e.g. 
downsizing) 
1 2 3 4 5 
Potential intellectual property (IP) theft in 
offshored location(s) 
1 2 3 4 5 
Security in offshored location 1 2 3 4 5 
Being able to automate manufacturing 
process 
1 2 3 4 5 
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Product quality in offshored location(s) 1 2 3 4 5 
Research and development (R&D) 
capability 
1 2 3 4 5 
R&D cost 1 2 3 4 5 
Economic environment in home country 1 2 3 4 5 
Industry clusters 1 2 3 4 5 
Market competition 1 2 3 4 5 
Currency exchange rate 1 2 3 4 5 
Corporate social responsibility (CSR) 
practice in offshored location(s) 




















Appendix H. Classification of items through Q sort 
No. Items Group Variable 
1 Company share value A CSV 
2 Product complexity A n/a 
3 Product standardization A n/a 
4 
Poor infrastructure (e.g. transportation, logistics, 
information systems, etc.) in offshored location(s) 
B Infrastructure 
5 High transportation cost in offshored location(s) B Infrastructure 
6 Lack of raw materials in offshored location(s) C Supply 
7 Proximity to suppliers C Supply 
8 
Requirement and management of contract 
manufacturer in offshored location(s) 
C Supply 
9 
Economies of scale (cost advantage through a large 





High coordination cost to process information 





High production cost (except labor) with 













14 Low flexibility in offshored location(s) D 
Cost 
performance 
15 Poor productivity in offshored locations D 
Cost 
performance 
16 Customer requirement for product specialization E Customer 
17 Proximity to market or customers E Customer 
18 
Customer perception of “Made in USA” products 
and associated service 
E Customer 
19 Long lead time from offshored location(s) E Customer 










Regulatory requirement for products imported to or 













Government and customer pressure to produce goods 





Environmental issues (e.g. natural disaster, 
environmental sustainability) in offshored location(s) 
H n/a 
27 Lack of qualified personnel in offshored location(s) I Labor 
28 Increasing labor cost in offshored location(s) I Labor 
29 Labor intensity I n/a 
30 




Difficulty in control and coordination with 
manufacturing in offshored location(s) 
J Management 
32 Corporate decision to downsize the company J n/a 
33 
Extra management needed for manufacturing and 
supply chain in offshored location(s) 
J n/a 
34 
Distance (physical distance and/or perceived 
difference) with offshored location(s) 
J Management 
35 Reorganization of the company J Management 
36 
Potential intellectual property (IP) theft in offshored 
location(s) 
K Security 
37 Security in offshored location K Security 
38 Being able to automate manufacturing process L Automation 
39 Technology intensity L n/a 
40 Poor quality in offshored location(s) M Quality 
41 High R&D cost associated with products N R&D 
42 
Unavailability of R&D and technology in offshored 
location(s) 
N R&D 
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